CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | insulin-sensitizing drug |
|
Accession: | CHEBI:50864
|
browse the term
|
Definition: | An agent which overcomes insulin resistance by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma). |
Synonyms: | related_synonym: | PPAR-gamma agonist; PPAR-gamma agonists; PPARgamma agonist; PPARgamma agonists; glitazonas; glitazone drug; glitazones; insulin sensitisers; insulin sensitizers; insulin-sensitising drug; insulin-sensitizing agent; peroxisome proliferator-activated receptor gamma agonist; peroxisome proliferator-activated receptor gamma agonists; proliferator activated receptor gamma agonist; proliferator activated receptor gamma agonists; thiazolidinediones; tiazolidinedionas |
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions affects export affects glutathionylation increases transport |
ISO |
[ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein] ABCC1 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog ABCC1 protein affects the glutathionylation of 15-deoxy-delta(12,14)-prostaglandin J2 |
CTD |
PMID:14979731 PMID:21728338 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
affects export |
ISO |
ABCC3 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog |
CTD |
PMID:14979731 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]] |
CTD |
PMID:18278065 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2 |
CTD |
PMID:19997560 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16611854 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BGLAP mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC2 protein |
CTD |
PMID:15498850 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC3 protein |
CTD |
PMID:15498850 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases cleavage |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of CASP3 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of CASP3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of CASP3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:11785780 PMID:15498850 PMID:16299251 PMID:23973622 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:15498850 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:15498850 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]] |
CTD |
PMID:12847270 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein] |
CTD |
PMID:15187150 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA] |
CTD |
PMID:23688403 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] |
CTD |
PMID:19429239 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNA2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNB1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCND3 protein |
CTD |
PMID:15729575 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNE1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDK2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CDKN1A 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1A protein |
CTD |
PMID:15254749 PMID:15729575 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1B protein |
CTD |
PMID:15729575 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CEBPA mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CFLAR protein |
CTD |
PMID:15498850 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of CHUK protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased phosphorylation of CHUK protein] |
CTD |
PMID:15498850 PMID:22245093 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of COL1A1 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]] |
CTD |
PMID:12604364 PMID:14998300 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Ddx58 |
DEXD/H-box helicase 58 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of DDX58 mRNA] |
CTD |
PMID:16303604 |
|
NCBI chr 5:56,486,584...56,536,898
Ensembl chr 5:56,500,734...56,536,772
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of and results in increased activity of EGR1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of EGR1 mRNA] |
CTD |
PMID:12468449 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Tretinoin] results in increased expression of FABP4 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FABP4 mRNA |
CTD |
PMID:9543393 PMID:12021203 PMID:16573735 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of FAS mRNA |
CTD |
PMID:16712844 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; wortmannin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA] |
CTD |
PMID:11457450 PMID:11687581 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; [ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein |
CTD |
PMID:21728338 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression decreases expression multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GFAP 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of GFAP mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in decreased expression of GFAP mRNA] |
CTD |
PMID:15254749 PMID:15994020 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTA3 mRNA |
CTD |
PMID:14652005 |
|
NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
ISO |
GSTM1 protein affects the metabolism of [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Glutathione] |
CTD |
PMID:14979731 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA]; Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein] |
CTD |
PMID:11600134 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Hdac1 |
histone deacetylase 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC1 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr 5:147,716,664...147,743,723
Ensembl chr 5:147,716,664...147,743,723
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC2 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr20:43,084,870...43,108,198
Ensembl chr20:43,084,870...43,108,198
|
|
G |
Hdac3 |
histone deacetylase 3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC3 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr18:31,073,057...31,094,347
Ensembl chr18:31,073,058...31,094,303
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
affects stability multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 affects the stability of HIF1A protein Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Buthionine Sulfoximine promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Dithiothreitol inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein] |
CTD |
PMID:17658243 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein; [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] ochratoxin A inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 protein |
CTD |
PMID:11078701 PMID:15618017 PMID:15994020 PMID:19136476 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions |
ISO |
HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA] |
CTD |
PMID:15618017 |
|
NCBI chr 7:117,538,523...117,565,478
Ensembl chr 7:117,538,523...117,565,478
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HSPB1 protein |
CTD |
PMID:16299251 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases expression decreases secretion |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IFNG protein |
CTD |
PMID:12847270 PMID:16844232 PMID:19888466 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA] |
CTD |
PMID:14998300 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression decreases activity |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in decreased abundance of Prostaglandins]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1B protein [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with IL1B protein] results in decreased secretion of IL1B protein 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of IL1B protein |
CTD |
PMID:11457450 PMID:12604364 PMID:14998300 PMID:15751073 PMID:16461118 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
decreases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1RN mRNA |
CTD |
PMID:15751073 |
|
NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2] |
CTD |
PMID:23688403 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:12604364 PMID:12847270 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified inhibits the reaction [INS protein results in increased secretion of Glucose]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of INS mRNA] |
CTD |
PMID:14625208 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA] |
CTD |
PMID:12847270 |
|
NCBI chr10:39,109,530...39,116,532
Ensembl chr10:39,109,522...39,116,531
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]] |
CTD |
PMID:12847270 |
|
NCBI chr 1:247,398,667...247,457,521
Ensembl chr 1:247,398,598...247,458,509
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein] |
CTD |
PMID:11457450 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Klf6 |
Kruppel-like factor 6 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein] |
CTD |
PMID:16611854 |
|
NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
|
|
G |
Lep |
leptin |
multiple interactions increases secretion |
ISO |
[Dexamethasone co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased secretion of LEP protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased secretion of LEP protein |
CTD |
PMID:11092516 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] |
CTD |
PMID:19922793 |
|
NCBI chr14:84,482,652...84,500,574
Ensembl chr14:84,482,674...84,500,642
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of LPL mRNA |
CTD |
PMID:12021203 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK1 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK1 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11687581 PMID:12083801 PMID:16611854 PMID:19888466 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK3 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11687581 PMID:12083801 PMID:16611854 PMID:19888466 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Med1 |
mediator complex subunit 1 |
multiple interactions |
ISO |
MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein] |
CTD |
PMID:16324150 |
|
NCBI chr10:86,101,560...86,145,271
Ensembl chr10:86,103,600...86,144,880
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Dactinomycin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA] |
CTD |
PMID:19136476 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of MMP9 mRNA] |
CTD |
PMID:19997048 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MTOR protein |
CTD |
PMID:16611854 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Nes |
nestin |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NES protein |
CTD |
PMID:15212945 |
|
NCBI chr 2:187,343,109...187,352,972
Ensembl chr 2:187,344,056...187,352,969
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased activity of NFE2L2 protein; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of NFE2L2 protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and affects the localization of NFE2L2 protein; manganese chloride inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NFE2L2 protein] |
CTD |
PMID:19136476 PMID:21728338 PMID:22245093 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases localization |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased localization of NFKB1 protein |
CTD |
PMID:11457450 PMID:16299251 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased degradation of NFKBIA protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:15498850 PMID:22245093 PMID:23688403 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases activity decreases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS2 protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA] |
CTD |
PMID:11457450 PMID:11890746 PMID:12847270 PMID:15684285 PMID:15994020 PMID:16461118 PMID:19997048 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases activity |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS3 protein |
CTD |
PMID:11890746 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
affects activity multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 affects the activity of NR3C1 protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Dexamethasone binds to NR3C1 protein] |
CTD |
PMID:15187150 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 protein] |
CTD |
PMID:22245093 |
|
NCBI chr 5:167,982,438...168,004,724
Ensembl chr 5:167,982,439...168,004,724
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of PARP1 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of PARP1 protein |
CTD |
PMID:15498850 PMID:23973622 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PCK1 mRNA |
CTD |
PMID:9518257 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARA protein |
CTD |
PMID:9013583 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARD protein |
CTD |
PMID:17341418 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects expression decreases response to substance increases expression increases activity multiple interactions decreases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 affects the expression of PPARG PPARG protein mutant form results in decreased susceptibility to 15-deoxy-delta(12,14)-prostaglandin J2 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of PPARG mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein] 15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased expression of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in decreased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased localization of and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [deoxynivalenol results in increased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of PPARG mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; MG 262 promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PPARG protein |
CTD |
PMID:9013583 PMID:10662598 PMID:11030710 PMID:12065695 PMID:12604364 PMID:12839938 PMID:12847270 PMID:14625208 PMID:14979731 PMID:14998300 PMID:15212945 PMID:15254749 PMID:15322177 PMID:15491415 PMID:15707588 PMID:15729575 PMID:15866424 PMID:15994020 PMID:16324150 PMID:16499875 PMID:17341418 PMID:18278065 PMID:18485432 PMID:19922793 PMID:23943857 PMID:26172262 PMID:30138673 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in increased expression of PTEN protein |
CTD |
PMID:16611854 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:19,195,606...19,196,508
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein] |
CTD |
PMID:12721327 PMID:16256979 |
|
NCBI chr 1:226,976,455...226,995,641
Ensembl chr 1:226,993,250...226,994,849
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
PTGS1 protein promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2] |
CTD |
PMID:17439952 |
|
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PTGS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PTGS2 |
CTD |
PMID:11457450 PMID:12604364 PMID:15254749 PMID:19997048 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptpn11 |
protein tyrosine phosphatase, non-receptor type 11 |
increases phosphorylation |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of PTPN11 protein |
CTD |
PMID:12584205 |
|
NCBI chr12:40,895,515...40,955,999
Ensembl chr12:40,895,515...40,955,999
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of and results in decreased phosphorylation of RAF1 protein |
CTD |
PMID:12083801 |
|
NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RARB |
CTD |
PMID:12839938 PMID:15254749 |
|
NCBI chr15:9,915,223...10,262,599
Ensembl chr15:10,120,206...10,262,599
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of and results in decreased expression of RB1 protein |
CTD |
PMID:15729575 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases activity |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased activity of RELA protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of RELA protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride affects the localization of RELA protein] |
CTD |
PMID:11457450 PMID:15498850 PMID:20174873 PMID:22245093 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rps6ka1 |
ribosomal protein S6 kinase A1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of RPS6KA1 protein |
CTD |
PMID:16611854 |
|
NCBI chr 5:152,078,217...152,122,684
Ensembl chr 5:152,078,220...152,122,684
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein] |
CTD |
PMID:16611854 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of RUNX2 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
|
|
G |
Rxra |
retinoid X receptor alpha |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RXRA |
CTD |
PMID:15254749 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]] |
CTD |
PMID:18278065 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] |
CTD |
PMID:19429239 |
|
NCBI chr18:72,550,107...72,612,078
Ensembl chr18:72,550,219...72,612,078
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS1 mRNA |
CTD |
PMID:12584205 |
|
NCBI chr10:4,956,795...4,958,472
Ensembl chr10:4,957,326...4,958,461
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS3 mRNA |
CTD |
PMID:12584205 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of SPP1 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [peroxyvanadate results in increased phosphorylation of STAT1 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]] |
CTD |
PMID:12584205 PMID:12847270 |
|
NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT3 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:12584205 PMID:12847270 PMID:19922793 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Tbxa2r |
thromboxane A2 receptor |
multiple interactions decreases expression |
ISO |
PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form] |
CTD |
PMID:16499875 |
|
NCBI chr 7:11,253,153...11,259,233
Ensembl chr 7:11,253,180...11,257,977
|
|
G |
Tg |
thyroglobulin |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TG protein |
CTD |
PMID:11078701 |
|
NCBI chr 7:107,467,260...107,652,897
Ensembl chr 7:107,467,260...107,652,899
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases expression decreases response to substance |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TGFB1 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [alitretinoin results in decreased expression of TGFB1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased susceptibility to TGFB1 protein |
CTD |
PMID:16611854 PMID:18278065 PMID:19429239 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Th |
tyrosine hydroxylase |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TH protein |
CTD |
PMID:15212945 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TLR2 mRNA |
CTD |
PMID:20174873 |
|
NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TNF protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:12604364 PMID:19888466 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein] |
CTD |
PMID:11078701 |
|
NCBI chr 2:205,207,799...205,215,199
Ensembl chr 2:205,207,799...205,212,681
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] |
CTD |
PMID:23688403 |
|
NCBI chr18:25,613,601...25,618,066
Ensembl chr18:25,613,831...25,617,361
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of VIM |
CTD |
PMID:15254749 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Wnt10b |
Wnt family member 10B |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of WNT10B mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 7:140,448,284...140,466,159
Ensembl chr 7:140,448,465...140,454,268
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of XIAP protein |
CTD |
PMID:15498850 PMID:16299251 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
decreases ubiquitination |
ISO |
bixin results in decreased ubiquitination of NFE2L2 protein |
CTD |
PMID:30698894 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
ciglitazone results in decreased activity of ABCB11 protein |
CTD |
PMID:20829430 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abhd3 |
abhydrolase domain containing 3, phospholipase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ABHD3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ABHD3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr18:1,892,413...1,946,840
Ensembl chr18:1,892,413...1,946,840
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of ACAA1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:128,027,880...128,036,471
Ensembl chr 8:128,027,958...128,036,236
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACAA2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr18:70,733,872...70,762,395
Ensembl chr18:70,733,872...70,762,395
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADM mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACADM mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:260,124,418...260,148,589
Ensembl chr 2:260,124,418...260,148,589
|
|
G |
Acadvl |
acyl-CoA dehydrogenase, very long chain |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADVL mRNA |
CTD |
PMID:16197558 |
|
NCBI chr10:56,619,321...56,624,468
Ensembl chr10:56,619,303...56,624,526
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of ACSL1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr16:48,937,456...49,003,898
Ensembl chr16:48,937,456...49,003,246
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACSM3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:189,514,504...189,541,233
Ensembl chr 1:189,514,553...189,541,224
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA] |
CTD |
PMID:18162602 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Agpat2 |
1-acylglycerol-3-phosphate O-acyltransferase 2 |
increases expression |
ISO |
ciglitazone results in increased expression of AGPAT2 mRNA |
CTD |
PMID:16847310 |
|
NCBI chr 3:4,044,741...4,055,384
Ensembl chr 3:4,044,542...4,055,806
|
|
G |
Agt |
angiotensinogen |
decreases response to substance |
EXP |
ciglitazone results in decreased susceptibility to AGT protein modified form |
CTD |
PMID:16820301 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Akap2 |
A-kinase anchoring protein 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PALM2AKAP2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:74,874,245...74,985,789
Ensembl chr 5:74,874,306...74,982,401
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
EXP |
ciglitazone results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Ang |
angiogenin |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANG mRNA |
CTD |
PMID:16197558 |
|
NCBI chr15:28,022,926...28,028,636
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANGPTL4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079
|
|
G |
Apom |
apolipoprotein M |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of APOM mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:5,120,473...5,123,073
Ensembl chr20:5,120,474...5,123,073
|
|
G |
Aqp1 |
aquaporin 1 |
decreases expression |
EXP |
ciglitazone results in decreased expression of AQP1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 4:85,551,503...85,563,683
Ensembl chr 4:85,551,502...85,569,360
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of AQP3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AQP3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ARHGEF2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:187,964,100...188,022,847
Ensembl chr 2:187,977,008...188,021,377
|
|
G |
Atf7ip2 |
activating transcription factor 7 interacting protein 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ATF7IP2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr10:5,476,205...5,519,893
Ensembl chr10:5,476,966...5,511,955
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
decreases expression |
EXP |
ciglitazone results in decreased expression of ATP1B1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr13:82,737,161...82,757,681
Ensembl chr13:82,737,159...82,758,004
|
|
G |
Atp1b3 |
ATPase Na+/K+ transporting subunit beta 3 |
decreases expression |
EXP |
ciglitazone results in decreased expression of ATP1B3 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 8:104,190,032...104,221,342
Ensembl chr 8:104,190,032...104,221,342
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
EXP |
ciglitazone results in increased expression of BAD protein |
CTD |
PMID:12065618 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions affects response to substance increases expression |
ISO EXP |
[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein] BAX mRNA affects the susceptibility to ciglitazone ciglitazone results in increased expression of BAX protein |
CTD |
PMID:12065618 PMID:15492468 PMID:21067863 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
ciglitazone results in decreased expression of BCL2 protein |
CTD |
PMID:15492468 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl6 |
BCL6, transcription repressor |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of BCL6 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr11:80,255,790...80,279,075
Ensembl chr11:80,255,790...80,279,075
|
|
G |
Bdh1 |
3-hydroxybutyrate dehydrogenase 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of BDH1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr11:72,577,547...72,619,435
Ensembl chr11:72,578,533...72,614,176
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of BHMT mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:23,236,573...23,256,158
Ensembl chr 2:23,236,575...23,256,158
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein] |
CTD |
PMID:21067863 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
ciglitazone results in decreased expression of BIRC5 |
CTD |
PMID:17940898 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Blvrb |
biliverdin reductase B |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of BLVRB mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:84,256,063...84,273,726
Ensembl chr 1:84,256,159...84,274,075
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
decreases expression |
EXP |
ciglitazone results in decreased expression of CADM1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 8:51,858,906...52,200,591
Ensembl chr 8:52,127,399...52,189,722
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
ISO |
[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; GAST protein inhibits the reaction [ciglitazone results in increased expression of CASP3 mRNA] |
CTD |
PMID:15387324 PMID:21067863 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein] |
CTD |
PMID:21067863 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein] |
CTD |
PMID:21067863 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CAT mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL20 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL20 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [Thioglycolates results in increased secretion of CCL5 protein] |
CTD |
PMID:12624547 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
ciglitazone results in decreased expression of CCNA2 protein |
CTD |
PMID:21080969 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression increases expression |
ISO EXP |
ciglitazone results in decreased expression of CCND1 ciglitazone results in increased expression of CCND1 mRNA ciglitazone results in decreased expression of CCND1 protein |
CTD |
PMID:12787395 PMID:18162602 PMID:20578043 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions decreases expression |
ISO EXP |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CDH1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CDH1 mRNA; ciglitazone results in increased expression of and results in increased activity of CDH1 protein ciglitazone results in decreased expression of CDH1 mRNA |
CTD |
PMID:12391285 PMID:16197558 PMID:22193206 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression multiple interactions |
ISO |
ciglitazone results in decreased expression of CDK1 protein CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein] |
CTD |
PMID:21080969 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression multiple interactions |
ISO EXP |
ciglitazone results in decreased expression of CDK4 protein ciglitazone results in decreased expression of CDK4 mRNA CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein] |
CTD |
PMID:20578043 PMID:21080969 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression increases expression |
ISO |
ciglitazone results in decreased expression of CDKN1A ciglitazone results in increased expression of CDKN1A protein |
CTD |
PMID:12787395 PMID:19140230 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
EXP |
ciglitazone results in increased expression of CDKN1B mRNA |
CTD |
PMID:20578043 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
EXP |
ciglitazone results in increased expression of CEBPB mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of CEBPD mRNA |
CTD |
PMID:16197558 |
|
NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases expression |
ISO |
ciglitazone results in decreased expression of CES1 mRNA |
CTD |
PMID:11409902 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Chmp5 |
charged multivesicular body protein 5 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of CHMP5 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:57,267,312...57,284,455
Ensembl chr 5:57,267,312...57,284,448
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CIDEC mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:145,377,482...145,390,497
Ensembl chr 4:145,377,431...145,390,497
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of CITED2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:12,823,363...12,825,806
Ensembl chr 1:12,823,363...12,825,786
|
|
G |
Cobll1 |
cordon-bleu WH2 repeat protein-like 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of COBLL1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:51,137,104...51,298,956
Ensembl chr 3:51,137,076...51,297,852
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
multiple interactions |
EXP |
ciglitazone inhibits the reaction [Triiodothyronine results in increased expression of COL10A1 mRNA] |
CTD |
PMID:16023420 |
|
NCBI chr20:41,180,295...41,190,664
Ensembl chr20:41,184,287...41,189,633
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
decreases expression |
EXP |
ciglitazone results in decreased expression of COL11A1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 2:216,863,423...217,056,523
Ensembl chr 2:216,863,428...217,056,523
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
EXP |
ciglitazone results in decreased expression of COL4A1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
|
|
G |
Col4a5 |
collagen type IV alpha 5 chain |
decreases expression |
EXP |
ciglitazone results in decreased expression of COL4A5 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr X:112,769,595...112,983,720
Ensembl chr X:112,769,645...112,983,685
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
decreases expression |
EXP |
ciglitazone results in decreased expression of COL5A1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 3:6,430,180...6,581,010
Ensembl chr 3:6,430,201...6,578,882
|
|
G |
Copa |
COPI coat complex subunit alpha |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of COPA mRNA |
CTD |
PMID:16197558 |
|
NCBI chr13:90,467,285...90,508,894
Ensembl chr13:90,467,265...90,508,932
|
|
G |
Cp |
ceruloplasmin |
decreases expression |
EXP |
ciglitazone results in decreased expression of CP mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Cpm |
carboxypeptidase M |
decreases expression |
EXP |
ciglitazone results in decreased expression of CPM mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 7:60,654,350...60,714,620
Ensembl chr 7:60,654,350...60,714,620
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions affects response to substance |
ISO |
ciglitazone inhibits the reaction [CREBBP protein binds to EGFR promoter]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein] CREBBP affects the susceptibility to ciglitazone |
CTD |
PMID:21080969 |
|
NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
|
|
G |
Cstb |
cystatin B |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CSTB mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:10,966,357...10,968,399
Ensembl chr20:10,966,331...10,968,432
|
|
G |
Ctsc |
cathepsin C |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CTSC mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:151,918,514...151,949,979
Ensembl chr 1:151,918,571...151,949,983
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYB5R3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 7:124,024,003...124,041,564
Ensembl chr 7:124,023,995...124,041,594
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYP1A2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CYP1A2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
ciglitazone promotes the reaction [Niflumic Acid results in increased expression of DDIT3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; DDIT3 results in increased susceptibility to [Niflumic Acid co-treated with ciglitazone]; Niflumic Acid promotes the reaction [ciglitazone results in increased expression of DDIT3 protein] |
CTD |
PMID:21067863 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
increases expression |
ISO |
ciglitazone results in increased expression of DGAT1 mRNA |
CTD |
PMID:16847310 |
|
NCBI chr 7:117,566,363...117,576,735
Ensembl chr 7:117,566,368...117,576,737
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions increases activity |
ISO |
PPARG protein promotes the reaction [ciglitazone results in increased activity of DIO2 protein] |
CTD |
PMID:19036883 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of DKK1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:248,952,896...248,956,579
Ensembl chr 1:248,895,738...248,898,607 Ensembl chr 1:248,895,738...248,898,607
|
|
G |
Dlc1 |
DLC1 Rho GTPase activating protein |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of DLC1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr16:58,776,489...59,247,752
Ensembl chr16:59,077,574...59,247,754
|
|
G |
Dnajb5 |
DnaJ heat shock protein family (Hsp40) member B5 |
increases expression |
EXP |
ciglitazone results in increased expression of DNAJB5 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 5:58,393,197...58,402,162
Ensembl chr 5:58,393,233...58,401,870
|
|
G |
Dok4 |
docking protein 4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of DOK4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of DOK4 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr19:10,563,423...10,574,094
Ensembl chr19:10,563,423...10,574,093
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
EXP |
ciglitazone results in increased expression of DUSP1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
decreases expression |
EXP |
ciglitazone results in decreased expression of EFEMP1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr14:113,202,382...113,294,993
Ensembl chr14:113,202,419...113,295,014
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of EFNA1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions decreases expression |
ISO |
ciglitazone inhibits the reaction [CREBBP protein binds to EGFR promoter]; ciglitazone inhibits the reaction [NCOA1 protein binds to EGFR promoter]; CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein] |
CTD |
PMID:21080969 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
increases phosphorylation multiple interactions |
ISO |
ciglitazone results in increased phosphorylation of EIF2A protein ciglitazone promotes the reaction [Niflumic Acid results in increased phosphorylation of EIF2A protein]; Niflumic Acid promotes the reaction [ciglitazone results in increased phosphorylation of EIF2A protein] |
CTD |
PMID:21067863 |
|
NCBI chr 2:148,722,343...148,755,781
Ensembl chr 2:148,722,231...148,755,520
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases phosphorylation |
ISO |
ciglitazone promotes the reaction [Niflumic Acid results in increased phosphorylation of EIF2AK3 protein]; Niflumic Acid promotes the reaction [ciglitazone results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:21067863 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Elf5 |
E74 like ETS transcription factor 5 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ELF5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ELF5 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:93,333,514...93,374,454
Ensembl chr 3:93,351,619...93,371,656
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression |
EXP |
ciglitazone results in increased expression of EMP1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 4:169,161,076...169,181,967
Ensembl chr 4:169,147,243...169,181,966
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of EPAS1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 6:10,306,508...10,385,239
Ensembl chr 6:10,306,405...10,387,265
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of FABP1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FABP1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO |
ciglitazone results in increased expression of FABP4 mRNA |
CTD |
PMID:16847310 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Fads1 |
fatty acid desaturase 1 |
multiple interactions increases expression |
ISO |
[beta-hydroxy simvastatin acid co-treated with ciglitazone] results in increased expression of FADS1 mRNA ciglitazone results in increased expression of FADS1 mRNA |
CTD |
PMID:17655842 |
|
NCBI chr 1:226,234,034...226,249,118
Ensembl chr 1:226,234,074...226,249,138
|
|
G |
Fam102a |
family with sequence similarity 102, member A |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of FAM102A mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:11,554,084...11,586,315
Ensembl chr 3:11,554,457...11,586,303
|
|
G |
Fam13a |
family with sequence similarity 13, member A |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of FAM13A mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FAM13A mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:89,183,180...89,281,282
Ensembl chr 4:89,183,768...89,281,222
|
|
G |
Flnb |
filamin B |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of FLNB mRNA |
CTD |
PMID:16197558 |
|
NCBI chr15:18,750,152...18,883,019
Ensembl chr15:18,750,118...18,883,005
|
|
G |
Flnc |
filamin C |
increases expression |
EXP |
ciglitazone results in increased expression of FLNC mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 4:56,710,934...56,738,779
Ensembl chr 4:56,711,049...56,738,791
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression increases expression |
ISO EXP |
ciglitazone results in decreased expression of FOS ciglitazone results in increased expression of FOS mRNA |
CTD |
PMID:12787395 PMID:22193206 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of FOXO1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
increases expression |
EXP |
ciglitazone results in increased expression of GADD45G mRNA |
CTD |
PMID:22193206 |
|
NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243
|
|
G |
Galnt2 |
polypeptide N-acetylgalactosaminyltransferase 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of GALNT2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GALNT2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr19:57,043,858...57,115,123
Ensembl chr19:57,047,830...57,115,132
|
|
G |
Gast |
gastrin |
multiple interactions |
ISO |
GAST protein inhibits the reaction [ciglitazone results in increased expression of CASP3 mRNA] |
CTD |
PMID:15387324 |
|
NCBI chr10:88,245,532...88,248,485
Ensembl chr10:88,245,532...88,248,484
|
|
G |
Gcn1 |
GCN1 activator of EIF2AK4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of GCN1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr12:46,728,684...46,789,696
Ensembl chr12:46,728,699...46,789,726
|
|
G |
Gk |
glycerol kinase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of GK mRNA |
CTD |
PMID:16197558 |
|
NCBI chr X:54,227,291...54,303,897
Ensembl chr X:54,227,397...54,303,864
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of GPX3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GPX3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr10:40,247,436...40,255,423
Ensembl chr10:40,247,436...40,255,422
|
|
G |
Gramd2b |
GRAM domain containing 2B |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of GRAMD2B mRNA |
CTD |
PMID:16197558 |
|
NCBI chr18:51,492,196...51,591,028
Ensembl chr18:51,492,196...51,591,026
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases expression |
EXP |
ciglitazone results in decreased expression of GSTM2 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
|
|
G |
Gys2 |
glycogen synthase 2 |
increases expression |
ISO |
ciglitazone results in increased expression of GYS2 mRNA; ciglitazone results in increased expression of GYS2 protein |
CTD |
PMID:17437057 |
|
NCBI chr 4:176,638,632...176,679,805
Ensembl chr 4:176,638,629...176,679,815
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of HADHA mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HADHA mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 6:27,589,840...27,628,921
Ensembl chr 6:27,589,657...27,629,175
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of HAMP mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression |
EXP |
ciglitazone results in decreased expression of HIF1A mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMGCS2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMGCS2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:200,452,623...200,480,785
Ensembl chr 2:200,452,624...200,479,423
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMOX1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMOX1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hpn |
hepsin |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of HPN mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:89,534,112...89,549,575
Ensembl chr 1:89,534,106...89,543,967
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
ciglitazone results in decreased expression of ICAM1 mRNA; ciglitazone results in decreased expression of ICAM1 protein |
CTD |
PMID:17425601 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Ier2 |
immediate early response 2 |
increases expression |
EXP |
ciglitazone results in increased expression of IER2 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr19:25,774,146...25,775,670
Ensembl chr19:25,774,143...25,775,659
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases secretion |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone results in decreased secretion of IFNG protein]; ciglitazone inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; ciglitazone inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA]; ciglitazone inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; T 0070907 inhibits the reaction [ciglitazone results in decreased secretion of IFNG protein] |
CTD |
PMID:12847270 PMID:16844232 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
ciglitazone inhibits the reaction [Thioglycolates results in increased secretion of IL1B protein] ciglitazone promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; Dexamethasone inhibits the reaction [ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]] |
CTD |
PMID:12517972 PMID:12624547 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of IL1R1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]] |
CTD |
PMID:21511917 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Mifepristone inhibits the reaction [ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]] |
CTD |
PMID:15684043 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of IL6ST mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:44,279,199...44,319,427
Ensembl chr 2:44,289,393...44,314,944
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA] |
CTD |
PMID:12847270 |
|
NCBI chr10:39,109,530...39,116,532
Ensembl chr10:39,109,522...39,116,531
|
|
G |
Itgb5 |
integrin subunit beta 5 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of ITGB5 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr11:70,056,500...70,172,164
Ensembl chr11:70,056,500...70,172,372
|
|
G |
Itih3 |
inter-alpha trypsin inhibitor, heavy chain 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ITIH3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr16:6,983,779...7,007,288
Ensembl chr16:6,992,062...7,007,287
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of JAG1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:130,079,361...130,114,781
Ensembl chr 3:130,079,361...130,114,770
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
EXP ISO |
ciglitazone results in increased expression of JUN mRNA ciglitazone results in increased expression of JUN mRNA; ciglitazone results in increased expression of JUN protein [Bucladesine co-treated with ciglitazone] results in increased expression of and results in increased phosphorylation of JUN protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of JUN mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of JUN mRNA] |
CTD |
PMID:19698295 PMID:22193206 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Klf4 |
Kruppel like factor 4 |
increases expression |
EXP |
ciglitazone results in increased expression of KLF4 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
|
|
G |
Lama1 |
laminin subunit alpha 1 |
decreases expression |
EXP |
ciglitazone results in decreased expression of LAMA1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 9:115,916,907...116,042,123
Ensembl chr 9:115,916,907...116,042,123
|
|
G |
Lamb2 |
laminin subunit beta 2 |
decreases expression |
EXP |
ciglitazone results in decreased expression of LAMB2 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 8:117,268,335...117,280,517
Ensembl chr 8:117,268,337...117,280,517
|
|
G |
Lgals3 |
galectin 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of LGALS3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr15:24,153,602...24,165,537
Ensembl chr15:24,141,651...24,165,537
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] |
CTD |
PMID:19922793 |
|
NCBI chr14:84,482,652...84,500,574
Ensembl chr14:84,482,674...84,500,642
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of LIPC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LIPC mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:77,272,582...77,398,485
Ensembl chr 8:77,272,570...77,398,248
|
|
G |
Lmcd1 |
LIM and cysteine-rich domains 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of LMCD1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:144,192,989...144,252,554
Ensembl chr 4:144,192,989...144,252,551
|
|
G |
Lox |
lysyl oxidase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of LOX mRNA |
CTD |
PMID:16197558 |
|
NCBI chr18:47,500,320...47,577,819
Ensembl chr18:47,500,330...47,577,819
|
|
G |
Lpcat1 |
lysophosphatidylcholine acyltransferase 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of LPCAT1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:32,379,431...32,429,917
Ensembl chr 1:32,379,432...32,429,917
|
|
G |
Lpcat3 |
lysophosphatidylcholine acyltransferase 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of LPCAT3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:157,181,722...157,222,997
Ensembl chr 4:157,181,795...157,222,996
|
|
G |
Map4k3 |
mitogen-activated protein kinase kinase kinase kinase 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAP4K3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 6:3,276,732...3,444,519
Ensembl chr 6:3,276,738...3,444,519
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation increases phosphorylation multiple interactions |
ISO EXP |
ciglitazone results in decreased phosphorylation of MAPK1 protein ciglitazone results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK1 protein]; Glutathione inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12083801 PMID:19140230 PMID:20578043 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAPK14 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation increases phosphorylation multiple interactions decreases expression |
ISO EXP |
ciglitazone results in decreased phosphorylation of MAPK3 protein ciglitazone results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK3 protein]; Glutathione inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [ciglitazone results in increased phosphorylation of MAPK3 protein] CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein] |
CTD |
PMID:12083801 PMID:19140230 PMID:20578043 PMID:21080969 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of MKI67 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
|
|
G |
Mogat1 |
monoacylglycerol O-acyltransferase 1 |
increases expression |
ISO |
ciglitazone results in increased expression of MOGAT1 mRNA |
CTD |
PMID:16847310 |
|
NCBI chr 9:84,405,481...84,418,657
Ensembl chr 9:84,405,477...84,418,591
|
|
G |
Mpc1 |
mitochondrial pyruvate carrier 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of MPC1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:53,026,608...53,038,229
Ensembl chr 1:53,026,608...53,038,229
|
|
G |
Mpzl2 |
myelin protein zero-like 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of MPZL2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:49,342,067...49,353,080
Ensembl chr 8:49,342,067...49,353,080
|
|
G |
Mtmr4 |
myotubularin related protein 4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of MTMR4 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr10:74,886,600...74,909,532
Ensembl chr10:74,886,985...74,909,533
|
|
G |
Mxra8 |
matrix remodeling associated 8 |
decreases expression |
EXP |
ciglitazone results in decreased expression of MXRA8 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 5:173,288,200...173,292,926
Ensembl chr 5:173,288,447...173,292,929
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions decreases expression |
ISO |
CREBBP protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein] |
CTD |
PMID:21080969 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions affects response to substance |
ISO |
ciglitazone inhibits the reaction [NCOA1 protein binds to EGFR promoter]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK1 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of CDK4 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of EGFR protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MAPK3 protein]; NCOA1 protein inhibits the reaction [ciglitazone results in decreased expression of MYC protein] NCOA1 affects the susceptibility to ciglitazone |
CTD |
PMID:21080969 |
|
NCBI chr 6:28,677,563...28,931,844
Ensembl chr 6:28,677,540...28,931,843
|
|
G |
Ndrg2 |
NDRG family member 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of NDRG2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr15:28,305,820...28,314,459
Ensembl chr15:28,305,821...28,314,459
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases activity |
ISO |
ciglitazone results in decreased activity of [RELA protein binds to NFKB1 protein] ciglitazone results in decreased activity of NFKB1 protein |
CTD |
PMID:17425601 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases expression |
ISO |
ciglitazone results in decreased expression of NFKBIA protein |
CTD |
PMID:12517972 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; ciglitazone inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:12031542 PMID:12847270 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of NPC1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr18:3,616,878...3,662,656
Ensembl chr18:3,616,878...3,662,683
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of NR1H3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
multiple interactions |
ISO |
NR2F1 protein promotes the reaction [[SR 11237 co-treated with ciglitazone] results in increased expression of RARB protein] |
CTD |
PMID:12839938 |
|
NCBI chr 2:5,569,954...5,579,894
Ensembl chr 2:5,569,935...5,579,894
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
affects localization |
ISO |
ciglitazone affects the localization of NR3C1 protein |
CTD |
PMID:15684043 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
G |
Nrep |
neuronal regeneration related protein |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of NREP mRNA |
CTD |
PMID:16197558 |
|
NCBI chr18:26,183,753...26,212,796
Ensembl chr18:26,185,259...26,211,445
|
|
G |
Oas1a |
2'-5' oligoadenylate synthetase 1A |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of OAS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OAS1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr12:41,200,680...41,211,393
Ensembl chr12:41,200,718...41,211,909
|
|
G |
Optn |
optineurin |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of OPTN mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OPTN mRNA |
CTD |
PMID:16197558 |
|
NCBI chr17:77,167,700...77,218,374
Ensembl chr17:77,167,740...77,218,389
|
|
G |
Osmr |
oncostatin M receptor |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of OSMR mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:56,107,491...56,163,522
Ensembl chr 2:56,110,777...56,151,531
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]; ciglitazone results in increased cleavage of and results in increased activity of PARP1 protein; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein] |
CTD |
PMID:15492468 PMID:21067863 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PCK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PCK1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pdzk1 |
PDZ domain containing 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PDZK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PDZK1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:198,965,685...198,999,323
Ensembl chr 2:198,965,685...198,999,323
|
|
G |
Phka2 |
phosphorylase kinase regulatory subunit alpha 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of PHKA2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr X:35,970,650...36,926,616
|
|
G |
Phlpp1 |
PH domain and leucine rich repeat protein phosphatase 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PHLPP1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr13:26,145,989...26,394,505
Ensembl chr13:26,172,243...26,394,505
|
|
G |
Pim1 |
Pim-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PIM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PIM1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:8,165,423...8,169,557
Ensembl chr20:8,165,307...8,169,555
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLA2G2A mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:157,282,650...157,285,295
Ensembl chr 5:157,282,669...157,285,328
|
|
G |
Plac8 |
placenta associated 8 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLAC8 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr14:10,692,799...10,714,556
Ensembl chr14:10,692,764...10,714,524
|
|
G |
Plcxd1 |
phosphatidylinositol-specific phospholipase C, X domain containing 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLCXD1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr12:52,640,939...52,645,153
Ensembl chr12:52,641,222...52,676,608
|
|
G |
Plin2 |
perilipin 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLIN2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PLIN2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:104,984,413...105,010,863
Ensembl chr 5:104,984,414...105,010,857
|
|
G |
Plod2 |
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 |
decreases expression |
EXP |
ciglitazone results in decreased expression of PLOD2 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 8:99,977,334...100,059,736
Ensembl chr 8:99,977,334...100,059,736
|
|
G |
Plscr4 |
phospholipid scramblase 4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLSCR4 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:99,880,073...99,917,733
Ensembl chr 8:99,880,073...99,918,825
|
|
G |
Pmm1 |
phosphomannomutase 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PMM1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 7:123,183,504...123,193,874
Ensembl chr 7:123,183,506...123,193,761
|
|
G |
Pnrc1 |
proline-rich nuclear receptor coactivator 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of PNRC1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:48,501,472...48,504,511
Ensembl chr 5:48,501,472...48,504,511
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of POR mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of POR mRNA |
CTD |
PMID:16197558 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions decreases expression increases expression |
ISO |
ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [ciglitazone results in increased expression of PPARA mRNA]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PPARA mRNA] ciglitazone results in decreased expression of PPARA mRNA |
CTD |
PMID:11056218 PMID:11840453 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions affects localization increases expression decreases response to substance affects binding increases localization increases activity |
ISO EXP |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ABHD3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACAA2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADM mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACADVL mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ACSM3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANG mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ANGPTL4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of APOL1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of APOM mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AQP3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ARHGEF2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ATF7IP2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BCL6 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BDH1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BHMT mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of BLVRB mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CAT mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL14 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL15 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CCL20 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CDH1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CIDEC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of COBLL1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of COPA mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CSTB mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CTSC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYB5R3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of CYP1A2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DKK1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DLC1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of DOK4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of EFNA1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ELF5 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FABP1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FAM102A mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FAM13A mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of FLNB mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GALNT2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GCN1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GK mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GK3P mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GPX3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of GRAMD2B mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HADHA mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HAMP mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMGCS2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HMOX1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of HPN mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ITIH3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LIPC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LMCD1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LOX mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of LPCAT1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAGED4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAGED4B mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAP4K3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MAPK14 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MKI67 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of MTMR4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NDRG2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NR1H3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of NREP mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of OAS1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of OPTN mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PALM2AKAP2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PCK1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PDZK1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PHLPP1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PIM1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLA2G2A mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLAC8 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLCXD1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLIN2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PLSCR4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PMM1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of POR mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PRKCD mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of PSD4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RETSAT mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNASE4 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNF128 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of RPS6KC1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of S100P mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEC23A mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEMA3G mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEPTIN10 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SERPINE1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC30A10 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC50A1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SNRK mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SORL1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SOWAHC mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of STBD1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of SUN2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TCAF1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TIMP3 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TMEM53 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TNS1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of TRAF3IP2 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A6 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A9 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of VEGFA mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of VNN1 mRNA; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of ZNF185 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ABHD3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACAA1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACADM mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ACSL1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ANGPTL4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AQP3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL14 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL15 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CCL20 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CDH1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CEBPD mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CHMP5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CITED2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of CYP1A2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of DOK4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ELF5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of EPAS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FABP1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FAM13A mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of FOXO1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GALNT2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of GPX3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HADHA mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HCAR3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMGCS2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of HMOX1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of IL1R1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of IL6ST mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of ITGB5 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of JAG1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LGALS3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LIPC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of LPCAT3 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of MPC1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of MPZL2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of NPC1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OAS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OPTN mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of OSMR mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PCK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PDZK1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PHKA2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PIM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PLIN2 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of PNRC1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of POR mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of RBMS1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of RNF10 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of S100P mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SERPINE1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SLC30A10 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SLC4A7 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SORL1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SOWAHC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SQSTM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of STBD1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of STX7 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TBC1D4 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TCAF1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TGIF1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TMBIM1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of VEGFA mRNA; ciglitazone binds to and results in decreased activity of PPARG protein; ciglitazone binds to and results in increased activity of PPARG protein; ciglitazone inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG mRNA]; ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]; monobutyl phthalate inhibits the reaction [ciglitazone binds to and results in increased activity of PPARG protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [ciglitazone results in increased expression of PPARG mRNA]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PPARG mRNA]; norathyriol inhibits the reaction [ciglitazone results in increased activity of PPARG protein]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 protein]; PPARG protein promotes the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]; PPARG protein promotes the reaction [ciglitazone results in increased activity of DIO2 protein]; Quercetin inhibits the reaction [ciglitazone results in increased activity of PPARG protein] ciglitazone affects the localization of PPARG protein ciglitazone results in increased expression of PPARG protein PPARG protein mutant form results in decreased susceptibility to ciglitazone ciglitazone results in increased localization of PPARG protein [ciglitazone co-treated with Bucladesine] affects the expression of PPARG mRNA; [ciglitazone co-treated with Bucladesine] results in increased expression of PPARG protein; ciglitazone binds to and results in increased activity of PPARG protein; ciglitazone inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; ciglitazone inhibits the reaction [PPARG protein results in increased susceptibility to Methamphetamine]; PPARG protein promotes the reaction [ciglitazone results in increased expression of PPARGC1A mRNA] [ciglitazone binds to and results in increased activity of PPARG protein] which results in increased transport of Glucose; ciglitazone binds to and results in increased activity of PPARG protein; ciglitazone inhibits the reaction [Glycerol results in decreased expression of PPARG protein] ciglitazone results in increased expression of PPARG mRNA; ciglitazone results in increased expression of PPARG protein |
CTD |
PMID:11030710 PMID:11343236 PMID:11683414 PMID:11840453 PMID:12391285 PMID:12517972 PMID:12604364 PMID:12839938 PMID:12847270 PMID:14512786 PMID:14998300 PMID:15187150 PMID:15866424 PMID:16023420 PMID:16197558 PMID:16326050 PMID:16386710 PMID:16417216 PMID:16513826 PMID:16820301 PMID:17019405 PMID:18063688 PMID:18162602 PMID:18393431 PMID:19036883 PMID:19698295 PMID:19922793 PMID:20578043 PMID:21067863 PMID:21354099 PMID:21511917 PMID:21543282 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO |
ciglitazone results in increased expression of PPARGC1A mRNA PPARG protein promotes the reaction [ciglitazone results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:16513826 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PRKCD mRNA |
CTD |
PMID:16197558 |
|
NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
|
|
G |
Prodh1 |
proline dehydrogenase 1 |
increases expression |
ISO |
ciglitazone results in increased expression of PRODH mRNA |
CTD |
PMID:17535976 |
|
NCBI chr11:87,058,478...87,075,785
Ensembl chr11:87,058,616...87,075,785
|
|
G |
Psd4 |
pleckstrin and Sec7 domain containing 4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of PSD4 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:1,478,432...1,515,094
Ensembl chr 3:1,478,525...1,514,934
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
EXP |
ciglitazone results in increased expression of PTEN protein |
CTD |
PMID:20578043 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptger3 |
prostaglandin E receptor 3 |
multiple interactions |
ISO |
[Cisplatin co-treated with ciglitazone] results in decreased expression of PTGER3 |
CTD |
PMID:21681689 |
|
NCBI chr 2:263,895,093...263,979,682
Ensembl chr 2:263,895,241...263,979,698
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
[Cisplatin co-treated with ciglitazone] results in decreased expression of PTGES |
CTD |
PMID:21681689 |
|
NCBI chr 3:9,727,408...9,738,752
Ensembl chr 3:9,727,408...9,738,752
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression affects expression |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [ciglitazone results in increased expression of PTGS2 protein]; [Cisplatin co-treated with ciglitazone] results in decreased expression of PTGS2; ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]; ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]; ciglitazone results in increased expression of and results in increased activity of PTGS2 protein; Dexamethasone inhibits the reaction [ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]]; Dexamethasone inhibits the reaction [ciglitazone results in increased expression of and results in increased activity of PTGS2 protein]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARA protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone promotes the reaction [PPARG protein results in increased expression of PTGS2 mRNA]]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; nimesulide inhibits the reaction [ciglitazone results in increased expression of PTGS2 protein]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 mRNA]; PPARG promotes the reaction [ciglitazone results in increased expression of PTGS2 protein] ciglitazone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]; ciglitazone results in increased expression of PTGS2 mRNA; ciglitazone results in increased expression of PTGS2 protein ciglitazone promotes the reaction [[PAR-1-activating peptide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; ciglitazone promotes the reaction [PAR-1-activating peptide results in increased expression of PTGS2 protein] ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; ciglitazone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] ciglitazone affects the expression of PTGS2 protein |
CTD |
PMID:11840453 PMID:12031542 PMID:12517972 PMID:16417216 PMID:19954759 PMID:21067863 PMID:21681689 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Pxdn |
peroxidasin |
decreases expression |
EXP |
ciglitazone results in decreased expression of PXDN mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 6:48,866,496...48,982,368
Ensembl chr 6:48,866,601...48,980,340
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
increases activity |
ISO |
ciglitazone results in increased activity of RAF1 protein |
CTD |
PMID:12083801 |
|
NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]; ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]; NR2F1 protein promotes the reaction [[SR 11237 co-treated with ciglitazone] results in increased expression of RARB protein]; PPARG protein promotes the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]] |
CTD |
PMID:12839938 |
|
NCBI chr15:9,915,223...10,262,599
Ensembl chr15:10,120,206...10,262,599
|
|
G |
Rbms1 |
RNA binding motif, single stranded interacting protein 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of RBMS1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 3:46,802,870...47,025,178
Ensembl chr 3:46,803,355...47,025,128
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases activity multiple interactions |
ISO |
ciglitazone results in decreased activity of RELA protein ciglitazone results in decreased activity of [RELA protein binds to NFKB1 protein] |
CTD |
PMID:17425601 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Retsat |
retinol saturase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of RETSAT mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:100,465,365...100,474,128
Ensembl chr 4:100,465,170...100,474,301
|
|
G |
RGD1564865 |
similar to 20-alpha-hydroxysteroid dehydrogenase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr17:69,468,427...69,497,132
Ensembl chr17:69,468,427...69,497,132
|
|
G |
Rnase4 |
ribonuclease A family member 4 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNASE4 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr15:28,018,040...28,035,395
Ensembl chr15:28,018,040...28,035,389 Ensembl chr15:28,018,040...28,035,389
|
|
G |
Rnf10 |
ring finger protein 10 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of RNF10 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr12:47,103,313...47,137,096
Ensembl chr12:47,103,314...47,138,128
|
|
G |
Rnf128 |
ring finger protein 128 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of RNF128 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr X:110,789,061...110,877,964
Ensembl chr X:110,789,269...110,877,978
|
|
G |
Rps6kc1 |
ribosomal protein S6 kinase C1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of RPS6KC1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr13:109,338,761...109,589,209
Ensembl chr13:109,338,762...109,483,891
|
|
G |
Sec23a |
Sec23 homolog A, COPII coat complex component |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEC23A mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 6:80,059,742...80,107,340
Ensembl chr 6:80,060,916...80,107,236
|
|
G |
Sema3g |
semaphorin 3G |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEMA3G mRNA |
CTD |
PMID:16197558 |
|
NCBI chr16:7,303,582...7,315,214
Ensembl chr16:7,303,578...7,315,390
|
|
G |
Septin10 |
septin 10 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SEPTIN10 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:28,722,479...28,814,841
Ensembl chr20:28,722,580...28,814,636
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SERPINE1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SERPINE1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Slc24a2 |
solute carrier family 24 member 2 |
decreases expression |
EXP |
ciglitazone results in decreased expression of SLC24A2 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 5:105,336,287...105,579,959
Ensembl chr 5:105,336,262...105,582,375
|
|
G |
Slc24a4 |
solute carrier family 24 member 4 |
decreases expression |
EXP |
ciglitazone results in decreased expression of SLC24A4 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 6:126,015,799...126,158,727
Ensembl chr 6:126,018,841...126,153,867
|
|
G |
Slc30a10 |
solute carrier family 30, member 10 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC30A10 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SLC30A10 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr13:103,396,295...103,406,759
Ensembl chr13:103,396,314...103,410,363
|
|
G |
Slc4a7 |
solute carrier family 4 member 7 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of SLC4A7 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr15:11,832,611...11,912,923
Ensembl chr15:11,836,286...11,912,916
|
|
G |
Slc50a1 |
solute carrier family 50 member 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SLC50A1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 2:188,585,118...188,587,498
Ensembl chr 2:188,585,118...188,587,498
|
|
G |
Snrk |
SNF related kinase |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SNRK mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:130,749,806...130,805,225
Ensembl chr 8:130,749,838...130,803,597
|
|
G |
Sod3 |
superoxide dismutase 3 |
decreases expression |
EXP |
ciglitazone results in decreased expression of SOD3 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr14:60,958,583...60,971,143
Ensembl chr14:60,958,592...60,964,324
|
|
G |
Sorl1 |
sortilin related receptor 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SORL1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SORL1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 8:46,228,077...46,287,171
|
|
G |
Sowahc |
sosondowah ankyrin repeat domain family member C |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SOWAHC mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of SOWAHC mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:28,815,039...28,819,505
Ensembl chr20:28,815,039...28,819,505
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of SQSTM1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
EXP |
ciglitazone results in increased expression of SRXN1 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 3:147,608,850...147,614,410
Ensembl chr 3:147,609,095...147,632,801
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression |
ISO |
[Bucladesine co-treated with ciglitazone] results in increased expression of STAR mRNA; [Bucladesine co-treated with ciglitazone] results in increased phosphorylation of STAR protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR protein]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR protein] |
CTD |
PMID:19698295 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] |
CTD |
PMID:19922793 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Stbd1 |
starch binding domain 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of STBD1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of STBD1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr14:16,976,355...16,979,760
Ensembl chr14:16,976,356...16,979,760
|
|
G |
Stx7 |
syntaxin 7 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of STX7 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:22,241,655...22,281,850
Ensembl chr 1:22,241,661...22,281,788
|
|
G |
Sun2 |
Sad1 and UNC84 domain containing 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of SUN2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 7:120,950,391...120,967,583
Ensembl chr 7:120,951,560...120,967,490
|
|
G |
Tbc1d4 |
TBC1 domain family, member 4 |
multiple interactions increases phosphorylation |
ISO EXP |
[ciglitazone binds to PPARG protein] which results in increased expression of TBC1D4 mRNA ciglitazone results in increased phosphorylation of TBC1D4 protein |
CTD |
PMID:16197558 PMID:18063688 |
|
NCBI chr15:85,927,978...86,105,829
Ensembl chr15:85,930,044...86,105,273
|
|
G |
Tcaf1 |
TRPM8 channel-associated factor 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of TCAF1 mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of TCAF1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 4:72,119,349...72,171,733
Ensembl chr 4:72,124,234...72,143,748
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; ciglitazone inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:18162602 PMID:27936102 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tgif1 |
TGFB-induced factor homeobox 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of TGIF1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:119,181,079...119,190,698
Ensembl chr 9:119,181,083...119,190,698
|
|
G |
Thra |
thyroid hormone receptor alpha |
decreases activity |
EXP |
ciglitazone results in decreased activity of THRA protein |
CTD |
PMID:16023420 |
|
NCBI chr10:86,657,285...86,684,935
Ensembl chr10:86,657,285...86,684,933
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of TIMP3 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 7:23,543,125...23,594,170
Ensembl chr 7:23,544,215...23,594,133
|
|
G |
Tmbim1 |
transmembrane BAX inhibitor motif containing 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein] which results in increased expression of TMBIM1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:81,569,289...81,586,469
Ensembl chr 9:81,569,289...81,586,553
|
|
G |
Tmem53 |
transmembrane protein 53 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of TMEM53 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 5:136,112,417...136,127,976
Ensembl chr 5:136,112,417...136,127,976
|
|
G |
Tnfrsf12a |
TNF receptor superfamily member 12A |
increases expression |
EXP |
ciglitazone results in increased expression of TNFRSF12A mRNA |
CTD |
PMID:22193206 |
|
NCBI chr10:12,995,904...12,997,930
Ensembl chr10:12,995,904...12,997,930
|
|
G |
Tns1 |
tensin 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of TNS1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:81,190,192...81,401,020
Ensembl chr 9:81,194,119...81,400,987
|
|
G |
Tpm3 |
tropomyosin 3 |
increases expression |
EXP |
ciglitazone results in increased expression of TPM3 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 2:189,423,534...189,451,340
Ensembl chr 2:189,423,559...189,451,029
|
|
G |
Traf3ip2 |
Traf3 interacting protein 2 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of TRAF3IP2 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr20:44,679,861...44,722,874
Ensembl chr20:44,680,449...44,722,872
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression |
EXP |
ciglitazone results in increased expression of TRIB3 mRNA |
CTD |
PMID:22193206 |
|
NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
|
|
G |
Ucp2 |
uncoupling protein 2 |
decreases expression |
ISO |
ciglitazone results in decreased expression of UCP2 mRNA |
CTD |
PMID:11056218 |
|
NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
|
|
G |
Ucp3 |
uncoupling protein 3 |
decreases expression |
ISO |
ciglitazone results in decreased expression of UCP3 mRNA |
CTD |
PMID:11056218 |
|
NCBI chr 1:165,482,912...165,495,895
Ensembl chr 1:165,482,155...165,496,206
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A6 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:95,241,609...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of UGT1A9 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 9:95,161,157...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
ISO |
[[Cisplatin co-treated with ciglitazone] results in decreased expression of VEGFA] which results in decreased abundance of Dinoprostone; [ciglitazone binds to PPARG protein alternative form] which results in increased expression of VEGFA mRNA; [ciglitazone binds to PPARG protein] which results in increased expression of VEGFA mRNA; [Cisplatin co-treated with ciglitazone] results in decreased expression of VEGFA ciglitazone results in increased expression of VEGFA mRNA |
CTD |
PMID:16197558 PMID:18599600 PMID:21681689 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vnn1 |
vanin 1 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of VNN1 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr 1:22,614,832...22,625,134
Ensembl chr 1:22,614,783...22,625,204
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
ciglitazone results in decreased expression of XIAP |
CTD |
PMID:17940898 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
G |
Zfp185 |
zinc finger protein 185 |
multiple interactions |
ISO |
[ciglitazone binds to PPARG protein alternative form] which results in increased expression of ZNF185 mRNA |
CTD |
PMID:16197558 |
|
NCBI chr X:152,989,099...153,034,289
Ensembl chr X:152,999,016...153,031,444
|
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABAT mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:7,093,406...7,200,439
Ensembl chr10:7,093,405...7,200,499
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
affects expression increases expression |
ISO |
pioglitazone affects the expression of ABCA1 protein pioglitazone results in increased expression of ABCA1 mRNA; pioglitazone results in increased expression of ABCA1 protein |
CTD |
PMID:15381068 PMID:17961437 PMID:19201410 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abca4 |
ATP binding cassette subfamily A member 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABCA4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:225,645,539...225,783,288
Ensembl chr 2:225,645,568...225,783,287
|
|
G |
Abca6 |
ATP binding cassette subfamily A member 6 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABCA6 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:98,477,716...98,546,699
Ensembl chr10:98,478,067...98,544,447
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABCA8B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:98,236,919...98,308,288
Ensembl chr10:98,237,141...98,294,522
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
pioglitazone results in decreased activity of ABCB11 protein |
CTD |
PMID:20829430 PMID:22646477 PMID:23956101 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
Pioglitazone results in increased expression of ABCB1 mRNA |
CTD |
PMID:31233785 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABCC9 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:176,806,098...176,928,540
Ensembl chr 4:176,805,431...176,922,424
|
|
G |
Abi3bp |
ABI family member 3 binding protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABI3BP mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:46,206,932...46,422,791
Ensembl chr11:46,208,075...46,369,577
|
|
G |
Ablim2 |
actin binding LIM protein family, member 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABLIM2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:80,044,217...80,169,491
Ensembl chr14:80,045,078...80,169,472
|
|
G |
Abra |
actin-binding Rho activating protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABRA mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:80,792,615...80,796,683
Ensembl chr 7:80,792,600...80,796,670
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases expression |
ISO |
pioglitazone results in decreased expression of ACAT1 mRNA |
CTD |
PMID:15381068 |
|
NCBI chr 8:58,166,990...58,195,884
Ensembl chr 8:58,166,990...58,195,884
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of ACAT2 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 1:47,972,399...47,992,654
Ensembl chr 1:47,972,399...47,992,653
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [Streptozocin results in increased expression of ACE mRNA]; pioglitazone inhibits the reaction [Streptozocin results in increased expression of ACE protein] |
CTD |
PMID:16979161 |
|
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
increases expression increases secretion |
EXP |
Pioglitazone results in increased expression of ACE2 protein Pioglitazone results in increased secretion of ACE2 protein |
CTD |
PMID:24114819 PMID:24558317 |
|
NCBI chr X:32,050,734...32,095,860
Ensembl chr X:32,049,931...32,096,016
|
|
G |
Acod1 |
aconitate decarboxylase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of ACOD1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr15:93,612,968...93,622,322
Ensembl chr15:93,612,971...93,622,358
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ACTA1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr19:56,674,072...56,677,084
Ensembl chr19:56,674,074...56,677,084
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP ISO |
pioglitazone affects the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] pioglitazone inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of ACTA2 mRNA]; pioglitazone inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:15052691 PMID:16484506 PMID:18513333 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Actc1 |
actin, alpha, cardiac muscle 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ACTC1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:105,507,403...105,512,939
Ensembl chr 3:105,507,403...105,512,939
|
|
G |
Actg2 |
actin gamma 2, smooth muscle |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ACTG2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:115,215,160...115,239,746
Ensembl chr 4:115,215,060...115,239,723
|
|
G |
Actn2 |
actinin alpha 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ACTN2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:66,304,530...66,397,647
Ensembl chr17:66,304,501...66,397,653
|
|
G |
Adam23 |
ADAM metallopeptidase domain 23 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ADAM23 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:70,133,969...70,293,312
Ensembl chr 9:70,133,969...70,290,117
|
|
G |
Adam5 |
ADAM metallopeptidase domain 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ADAM5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:72,010,069...72,085,666
Ensembl chr16:72,010,106...72,077,916
|
|
G |
Adam9 |
ADAM metallopeptidase domain 9 |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ADAM9 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr16:71,810,377...71,887,926
Ensembl chr16:71,810,377...71,887,926
|
|
G |
Adcy5 |
adenylate cyclase 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ADCY5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:68,695,839...68,842,452
Ensembl chr11:68,695,839...68,842,320
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ADCYAP1R1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:85,662,809...85,711,696
Ensembl chr 4:85,662,892...85,711,696
|
|
G |
Adhfe1 |
alcohol dehydrogenase, iron containing, 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ADHFE1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:9,403,194...9,429,783
Ensembl chr 5:9,403,196...9,429,859
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions decreases expression increases expression |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [Pioglitazone results in increased expression of ADIPOQ mRNA]; [N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of ADIPOQ mRNA; [Sodium Glutamate co-treated with Pioglitazone] results in increased expression of ADIPOQ protein; Pioglitazone promotes the reaction [Palmitates results in increased secretion of ADIPOQ protein]; PPARG protein affects the reaction [Pioglitazone results in increased expression of ADIPOQ mRNA] Pioglitazone results in decreased expression of ADIPOQ protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]]; Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; Pioglitazone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; T 0070907 inhibits the reaction [Pioglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]] Pioglitazone inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein]; Pioglitazone inhibits the reaction [Fructose results in decreased secretion of ADIPOQ protein] pioglitazone results in increased expression of ADIPOQ mRNA; pioglitazone results in increased expression of ADIPOQ protein |
CTD |
PMID:12927809 PMID:18303122 PMID:18513333 PMID:18815186 PMID:19048458 PMID:24622831 PMID:25679220 PMID:27918843 PMID:27935865 PMID:31016361 PMID:32407875 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Adm |
adrenomedullin |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ADM mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ADORA1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:51,042,111...51,076,913
Ensembl chr13:51,042,248...51,076,852
|
|
G |
Agbl1 |
AGBL carboxypeptidase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AGBL1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:137,798,862...138,711,126
Ensembl chr 1:137,799,185...138,711,126
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
EXP |
Pioglitazone inhibits the reaction [Fructose results in increased expression of AGER protein] |
CTD |
PMID:25679220 |
|
NCBI chr20:4,363,152...4,366,079
Ensembl chr20:4,363,152...4,366,079
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [AGT protein results in increased expression of KLF5 mRNA]; pioglitazone inhibits the reaction [AGT protein results in increased expression of KLF5 protein] |
CTD |
PMID:25874449 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AGTR1A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
ISO |
[ANGPT2 protein binds to and results in increased activity of AGTR2 protein] promotes the reaction [pioglitazone binds to and results in increased activity of PPARG protein]; [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AGTR2 mRNA |
CTD |
PMID:15992368 PMID:27935865 |
|
NCBI chr X:119,389,480...119,393,845
Ensembl chr X:119,390,013...119,393,842
|
|
G |
Aifm3 |
apoptosis inducing factor, mitochondria associated 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AIFM3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:87,364,452...87,380,705
Ensembl chr11:87,366,621...87,380,704
|
|
G |
Ajuba |
ajuba LIM protein |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AJUBA mRNA |
CTD |
PMID:20847119 |
|
NCBI chr15:33,208,210...33,218,456
Ensembl chr15:33,208,216...33,218,456
|
|
G |
Alpk3 |
alpha-kinase 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ALPK3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:142,882,997...142,931,940
Ensembl chr 1:142,883,040...142,931,940
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AMIGO2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:138,704,124...138,707,221
Ensembl chr 7:138,704,126...138,707,221
|
|
G |
Amotl2 |
angiomotin like 2 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of AMOTL2 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 8:111,210,261...111,226,217
Ensembl chr 8:111,209,908...111,226,226
|
|
G |
Ampd1 |
adenosine monophosphate deaminase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AMPD1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:205,568,934...205,589,961
Ensembl chr 2:205,568,935...205,590,021
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
ISO |
[ANGPT2 protein binds to and results in increased activity of AGTR2 protein] promotes the reaction [pioglitazone binds to and results in increased activity of PPARG protein] |
CTD |
PMID:15992368 |
|
NCBI chr16:75,966,480...76,016,147
Ensembl chr16:75,966,352...76,016,195
|
|
G |
Angptl2 |
angiopoietin-like 2 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANGPTL2 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANGPTL2 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 3:12,262,822...12,292,665
Ensembl chr 3:12,262,822...12,292,663
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
Pioglitazone results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079
|
|
G |
Ank1 |
ankyrin 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ANK1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:73,681,422...73,912,605
Ensembl chr16:73,681,422...73,827,488
|
|
G |
Ankrd37 |
ankyrin repeat domain 37 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ANKRD37 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ANKRD37 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr16:49,463,016...49,465,905
Ensembl chr16:49,462,889...49,465,888
|
|
G |
Ankrd63 |
ankyrin repeat domain 63 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ANKRD63 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:110,488,092...110,496,876
Ensembl chr 3:110,491,226...110,492,398
|
|
G |
Ano5 |
anoctamin 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ANO5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:106,873,580...106,971,769
Ensembl chr 1:106,896,790...106,968,885
|
|
G |
Anos1 |
anosmin 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of WFDC17 mRNA |
CTD |
PMID:27935865 |
|
Ensembl chr10:70,999,780...71,000,627
|
|
G |
Aoc3 |
amine oxidase, copper containing 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AOC3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:89,251,370...89,259,313
Ensembl chr10:89,251,370...89,259,313
|
|
G |
Ap1s2 |
adaptor related protein complex 1 subunit sigma 2 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of AP1S2 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr X:32,329,883...32,376,301
Ensembl chr X:32,329,598...32,355,307
|
|
G |
Apc2 |
APC regulator of WNT signaling pathway 2 |
increases expression |
ISO |
pioglitazone results in increased expression of APC2 mRNA |
CTD |
PMID:21347706 |
|
NCBI chr 7:12,258,468...12,280,459
Ensembl chr 7:12,258,468...12,275,609
|
|
G |
Apob |
apolipoprotein B |
decreases expression |
ISO |
pioglitazone results in decreased expression of APOB protein |
CTD |
PMID:16324916 |
|
NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
|
|
G |
Apoc1 |
apolipoprotein C1 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in increased expression of APOC1 protein |
CTD |
PMID:16324916 |
|
NCBI chr 1:80,606,638...80,609,921
Ensembl chr 1:80,606,638...80,609,921
|
|
G |
Apoc2 |
apolipoprotein C2 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC2 protein [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of APOC2 mRNA |
CTD |
PMID:16324916 PMID:27935865 |
|
NCBI chr 1:80,589,023...80,593,991
Ensembl chr 1:80,589,023...80,594,136
|
|
G |
Apoc3 |
apolipoprotein C3 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC3 protein |
CTD |
PMID:16324916 |
|
NCBI chr 8:50,529,318...50,531,498
Ensembl chr 8:50,529,318...50,531,498
|
|
G |
Apol9a |
apolipoprotein L 9a |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of APOL6 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:118,927,013...118,933,778
Ensembl chr 7:118,927,008...118,933,812
|
|
G |
App |
amyloid beta precursor protein |
decreases expression multiple interactions |
ISO |
pioglitazone results in decreased expression of APP protein mutant form pioglitazone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased metabolism of and results in increased secretion of APP protein alternative form]; pioglitazone inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased metabolism of and results in increased secretion of APP protein alternative form] |
CTD |
PMID:14586007 PMID:15817521 PMID:16407166 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Aqp7 |
aquaporin 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AQP7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:57,358,297...57,372,332
Ensembl chr 5:57,358,327...57,372,239
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AR mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Areg |
amphiregulin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of AREG mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
|
|
G |
Armcx2 |
armadillo repeat containing, X-linked 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ARMCX2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:105,617,383...105,622,209
Ensembl chr X:105,617,385...105,622,156
|
|
G |
Art1 |
ADP-ribosyltransferase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ART1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:167,202,064...167,206,615
Ensembl chr 1:167,197,549...167,206,614
|
|
G |
Asb10 |
ankyrin repeat and SOCS box-containing 10 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ASB10 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:7,158,293...7,167,505
Ensembl chr 4:7,158,448...7,167,509
|
|
G |
Asb14 |
ankyrin repeat and SOCS box-containing 14 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ASB14 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:2,537,209...2,556,930
Ensembl chr16:2,537,248...2,556,735
|
|
G |
Asb5 |
ankyrin repeat and SOCS box-containing 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ASB5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:39,985,233...40,050,663
Ensembl chr16:39,985,234...40,025,401
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of ATF3 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ATP1A2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:90,651,682...90,676,629
Ensembl chr13:90,651,686...90,676,629
|
|
G |
Atp2a1 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ATP2A1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:197,855,912...197,875,038
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
decreases expression |
ISO |
pioglitazone results in decreased expression of ATP5F1B mRNA |
CTD |
PMID:20860658 |
|
NCBI chr 7:2,504,708...2,511,748
Ensembl chr 7:2,504,695...2,511,749
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of AVPR1A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:67,341,366...67,345,290
Ensembl chr 7:67,341,080...67,345,308
|
|
G |
B4galnt2 |
beta-1,4-N-acetyl-galactosaminyl transferase 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of B4GALNT2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:83,677,768...83,701,487
|
|
G |
B4galnt3 |
beta-1,4-N-acetyl-galactosaminyl transferase 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of B4GALNT3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:152,736,036...152,835,521
Ensembl chr 4:152,737,161...152,835,182
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions decreases expression decreases activity |
ISO |
pioglitazone inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased expression of and results in increased activity of BACE1 protein] pioglitazone results in decreased expression of BACE1 mRNA; pioglitazone results in decreased expression of BACE1 protein pioglitazone results in decreased activity of BACE1 protein |
CTD |
PMID:14586007 PMID:15817521 PMID:16407166 |
|
NCBI chr 8:50,140,092...50,162,388
Ensembl chr 8:50,139,997...50,162,361
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
[naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of BAX mRNA]; Pioglitazone inhibits the reaction [Quinolinic Acid results in increased expression of BAX mRNA] |
CTD |
PMID:30130594 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of BCHE mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Bcl11a |
BAF chromatin remodeling complex subunit BCL11A |
decreases expression |
ISO |
Pioglitazone results in decreased expression of BCL11A mRNA |
CTD |
PMID:30031879 |
|
NCBI chr14:108,826,717...108,921,197
Ensembl chr14:108,826,831...108,921,669
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
[naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in decreased expression of BCL2 mRNA]; Pioglitazone inhibits the reaction [Quinolinic Acid results in decreased expression of BCL2 mRNA] |
CTD |
PMID:30130594 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bend5 |
BEN domain containing 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of BEND5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:131,257,127...131,312,335
Ensembl chr 5:131,257,127...131,312,335
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA] |
CTD |
PMID:32473317 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Bhlha15 |
basic helix-loop-helix family, member a15 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of BHLHA15 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr12:12,403,385...12,409,103
Ensembl chr12:12,403,385...12,407,561
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of BIRC3 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
increases expression |
ISO |
Pioglitazone results in increased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820
|
|
G |
Bpifa5 |
BPI fold containing family A, member 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of BPIFA5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:149,643,481...149,649,398
Ensembl chr 3:149,643,481...149,649,398
|
|
G |
Bpifb1 |
BPI fold containing family B, member 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of BPIFB1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:149,668,099...149,702,399
Ensembl chr 3:149,668,102...149,702,399
|
|
G |
Bsg |
basigin (Ok blood group) |
multiple interactions decreases expression |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein]]; pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG mRNA]; pioglitazone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein] pioglitazone results in decreased expression of BSG protein |
CTD |
PMID:16860414 PMID:17007354 PMID:17055343 |
|
NCBI chr 7:12,875,536...12,882,753
Ensembl chr 7:12,875,537...12,882,753
|
|
G |
Btn2a2 |
butyrophilin, subfamily 2, member A2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of BTN2A2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:43,867,243...43,878,734
Ensembl chr17:43,868,191...43,879,839
|
|
G |
Bzw1 |
basic leucine zipper and W2 domains 1 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of BZW1 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BZW1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 9:65,279,675...65,293,471
Ensembl chr 9:65,279,675...65,291,651
|
|
G |
C1qtnf7 |
C1q and TNF related 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of C1QTNF7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:72,011,518...72,122,257
Ensembl chr14:72,011,461...72,122,158
|
|
G |
C2H1orf54 |
chromosome 2 C1orf54 homolog |
decreases expression |
ISO |
Pioglitazone results in decreased expression of C1ORF54 mRNA |
CTD |
PMID:30031879 |
|
|
|
G |
C4a |
complement C4A |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of C4A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:2,651,599...2,678,183
Ensembl chr20:2,651,599...2,678,141
|
|
G |
C5ar1 |
complement C5a receptor 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of C5AR1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:78,186,777...78,195,132
Ensembl chr 1:78,186,776...78,195,328
|
|
G |
Ca3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CAR3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:88,126,519...88,136,063
Ensembl chr 2:88,126,667...88,135,410
|
|
G |
Cabcoco1 |
ciliary associated calcium binding coiled-coil 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CABCOCO1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:21,316,770...21,426,036
Ensembl chr20:21,316,826...21,426,034
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CACNA1C mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:150,635,808...151,270,790
Ensembl chr 4:150,641,066...150,829,913
|
|
G |
Cacna1s |
calcium voltage-gated channel subunit alpha1 S |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CACNA1S mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:52,889,570...52,964,558
Ensembl chr13:52,889,737...52,964,155
|
|
G |
Cacna2d3 |
calcium voltage-gated channel auxiliary subunit alpha2delta 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CACNA2D3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:4,871,348...5,795,825
Ensembl chr16:4,871,650...5,795,825
|
|
G |
Cadm2 |
cell adhesion molecule 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CADM2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:4,175,078...4,397,335
Ensembl chr11:4,174,881...4,397,361
|
|
G |
Calhm5 |
calcium homeostasis modulator family member 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CALHM5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:27,651,817...27,673,817
Ensembl chr20:27,651,312...27,657,983
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
pioglitazone inhibits the reaction [Galactose results in increased activity of CASP3 protein] [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of CASP3 mRNA]; Pioglitazone inhibits the reaction [Quinolinic Acid results in increased expression of CASP3 mRNA] |
CTD |
PMID:23795773 PMID:30130594 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casq1 |
calsequestrin 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CASQ1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:90,592,676...90,602,365
Ensembl chr13:90,592,681...90,602,365
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [pioglitazone inhibits the reaction [Quinolinic Acid results in decreased activity of CAT protein]]; pioglitazone inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased activity of CAT protein]; pioglitazone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; pioglitazone inhibits the reaction [Quinolinic Acid results in decreased activity of CAT protein] |
CTD |
PMID:20450929 PMID:27350165 PMID:29247773 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cav1 |
caveolin 1 |
affects expression |
ISO |
pioglitazone affects the expression of CAV1 protein |
CTD |
PMID:17961437 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Cav3 |
caveolin 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CAV3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:144,382,945...144,398,919
Ensembl chr 4:144,382,945...144,398,917
|
|
G |
Ccdc159 |
coiled-coil domain containing 159 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CCDC159 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:22,937,962...22,946,648
Ensembl chr 8:22,937,916...22,946,358
|
|
G |
Ccdc85a |
coiled-coil domain containing 85A |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CCDC85A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:112,719,482...112,900,724
Ensembl chr14:112,719,482...112,946,875
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of CCL11 protein] |
CTD |
PMID:17015710 |
|
NCBI chr10:69,434,965...69,439,566
Ensembl chr10:69,434,941...69,439,575
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCL2 mRNA [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CCL2 mRNA |
CTD |
PMID:20847119 PMID:27935865 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions decreases expression |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CCL3 mRNA Pioglitazone results in decreased expression of CCL3 mRNA |
CTD |
PMID:27935865 PMID:30031879 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions decreases response to substance |
ISO |
pioglitazone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of CCL5 protein] pioglitazone results in decreased susceptibility to CCL5 protein |
CTD |
PMID:17015710 PMID:18158351 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CCL7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO EXP |
[Pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of CCN2 mRNA; Pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of CCN2 mRNA] Pioglitazone affects the reaction [Carbon Tetrachloride results in increased expression of CCN2 mRNA] |
CTD |
PMID:16484506 PMID:20847119 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccna1 |
cyclin A1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CCNA1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:144,456,689...144,503,570
Ensembl chr 2:144,458,153...144,467,912
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
pioglitazone results in decreased expression of CCNA2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
pioglitazone results in decreased expression of CCNB1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
pioglitazone results in decreased expression of CCND1 mRNA; pioglitazone results in decreased expression of CCND1 protein pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of CCND1 protein] Pioglitazone results in decreased expression of CCND1 mRNA |
CTD |
PMID:17077279 PMID:26643070 PMID:30031879 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
pioglitazone results in decreased expression of CCND3 protein |
CTD |
PMID:15729575 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
pioglitazone results in decreased expression of CCNE1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Ccno |
cyclin O |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CCNO mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:44,857,043...44,860,317
Ensembl chr 2:44,857,213...44,860,315
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO EXP |
Pioglitazone results in increased expression of CD36 mRNA; Pioglitazone results in increased expression of CD36 protein PPARG protein affects the reaction [pioglitazone results in increased expression of CD36 protein] [pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CD36 mRNA pioglitazone results in increased expression of CD36 mRNA |
CTD |
PMID:15381068 PMID:16484506 PMID:17143554 PMID:19048458 PMID:20723549 PMID:26643070 PMID:28263783 PMID:30031879 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cd84 |
CD84 molecule |
decreases expression |
ISO |
Pioglitazone results in decreased expression of CD84 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr13:90,241,369...90,283,625
Ensembl chr13:90,244,681...90,277,865
|
|
G |
Cdc20b |
cell division cycle 20B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CDC20B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:44,916,806...44,947,860
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of CDC42 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 5:155,690,267...155,728,385
Ensembl chr 5:155,691,390...155,728,300
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
pioglitazone results in decreased expression of CDK2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkl1 |
cyclin dependent kinase like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CDKL1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 6:92,076,247...92,123,108
Ensembl chr 6:92,077,416...92,121,351
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions decreases expression |
EXP ISO |
pioglitazone inhibits the reaction [2-Acetylaminofluorene inhibits the reaction [Diethylnitrosamine results in decreased expression of CDKN1A protein]]; pioglitazone promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN1A protein] Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]]; Pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of CDKN1A protein]; Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]; Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in increased expression of CDKN1A protein]]; PRNP protein promotes the reaction [Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]]]; PRNP protein promotes the reaction [Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in increased expression of CDKN1A protein]]] pioglitazone results in decreased expression of CDKN1A protein |
CTD |
PMID:15729575 PMID:17582756 PMID:26643070 PMID:29734669 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases expression |
EXP ISO |
pioglitazone inhibits the reaction [2-Acetylaminofluorene promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN1B protein]]; pioglitazone promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN1B protein] pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased degradation of CDKN1B protein]; PRKAA1 protein affects the reaction [pioglitazone results in increased expression of CDKN1B protein] |
CTD |
PMID:17582756 PMID:26643070 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CDKN1C mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
pioglitazone results in increased expression of CEBPA mRNA |
CTD |
PMID:28242381 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Cemip |
cell migration inducing hyaluronidase |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CEMIP mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:146,069,774...146,226,320
Ensembl chr 1:146,069,771...146,226,462
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression |
ISO |
pioglitazone results in increased expression of CES1 mRNA |
CTD |
PMID:15381068 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Cfd |
complement factor D |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CFD mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:12,634,216...12,635,939
Ensembl chr 7:12,634,216...12,635,943
|
|
G |
Chchd6 |
coiled-coil-helix-coiled-coil-helix domain containing 6 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of CHCHD6 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 4:121,340,952...121,565,222
Ensembl chr 4:121,340,952...121,565,212
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CHIL1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:51,022,844...51,030,797
Ensembl chr13:51,022,681...51,030,802
|
|
G |
Chit1 |
chitinase 1 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of CHIT1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr13:50,947,020...50,994,644
Ensembl chr13:50,974,872...50,994,643
|
|
G |
Chp2 |
calcineurin-like EF hand protein 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CHP2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:192,169,634...192,173,228
Ensembl chr 1:192,169,841...192,173,253
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CHRM1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CHRM2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:64,089,028...64,091,090
Ensembl chr 4:64,088,900...64,091,090
|
|
G |
Chrna1 |
cholinergic receptor nicotinic alpha 1 subunit |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CHRNA1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:60,445,657...60,460,724
Ensembl chr 3:60,445,666...60,460,724
|
|
G |
Chrne |
cholinergic receptor nicotinic epsilon subunit |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CHRNE mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:57,238,960...57,246,750
Ensembl chr10:57,238,946...57,243,435
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of CHUK mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CIDEC mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:145,377,482...145,390,497
Ensembl chr 4:145,377,431...145,390,497
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CKM mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:80,321,507...80,331,841
Ensembl chr 1:80,321,585...80,331,841
|
|
G |
Ckmt2 |
creatine kinase, mitochondrial 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CKMT2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:21,422,680...21,452,797
Ensembl chr 2:21,422,818...21,437,193
|
|
G |
Clec14a |
C-type lectin domain containing 14A |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CLEC14A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 6:79,303,301...79,306,443
Ensembl chr 6:79,303,304...79,306,443
|
|
G |
Clec1a |
C-type lectin domain family 1, member A |
increases expression |
ISO |
Pioglitazone results in increased expression of CLEC1A mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 4:163,191,503...163,214,678
Ensembl chr 4:163,191,503...163,214,678
|
|
G |
Clec4a3 |
C-type lectin domain family 4, member A3 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of CLEC4A mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 4:155,913,366...155,923,079
Ensembl chr 4:155,913,366...155,923,079
|
|
G |
Clec4d |
C-type lectin domain family 4, member D |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CLEC4D mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:156,253,084...156,264,766
Ensembl chr 4:156,253,079...156,264,769
|
|
G |
Clec4e |
C-type lectin domain family 4, member E |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CLEC4E mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:156,271,087...156,276,243
Ensembl chr 4:156,270,920...156,276,304
|
|
G |
Clstn3 |
calsyntenin 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:157,044,736...157,078,013
Ensembl chr 4:157,043,925...157,078,130
|
|
G |
Cmya5 |
cardiomyopathy associated 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CMYA5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:22,646,694...22,744,536
Ensembl chr 2:22,646,712...22,744,407
|
|
G |
Cnga3 |
cyclic nucleotide gated channel subunit alpha 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CNGA3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:43,807,412...43,858,225
Ensembl chr 9:43,807,677...43,854,396
|
|
G |
Cnn1 |
calponin 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CNN1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:23,113,083...23,121,748
Ensembl chr 8:23,113,048...23,121,761
|
|
G |
Cnrip1 |
cannabinoid receptor interacting protein 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CNRIP1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:100,217,547...100,247,235
Ensembl chr14:100,217,289...100,247,235
|
|
G |
Cntd1 |
cyclin N-terminal domain containing 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CNTD1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:89,199,988...89,210,369
Ensembl chr10:89,199,880...89,209,393
|
|
G |
Cog8 |
component of oligomeric golgi complex 8 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of COG8 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr19:39,246,656...39,257,406
Ensembl chr19:39,246,625...39,257,451
|
|
G |
Col6a5 |
collagen type VI alpha 5 chain |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of COL6A5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:114,527,807...114,632,152
Ensembl chr 8:114,529,016...114,617,466
|
|
G |
Coro6 |
coronin 6 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CORO6 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:62,691,952...62,700,658
Ensembl chr10:62,691,953...62,699,723
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of COX6A2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:199,624,037...199,626,255
Ensembl chr 1:199,624,037...199,624,783
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
increases expression |
ISO |
pioglitazone results in increased expression of CPT1B mRNA |
CTD |
PMID:20723549 |
|
NCBI chr 7:130,395,211...130,404,731
Ensembl chr 7:130,395,194...130,405,347
|
|
G |
Cpxm1 |
carboxypeptidase X (M14 family), member 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CPXM1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:122,913,886...122,920,684
Ensembl chr 3:122,913,886...122,920,684
|
|
G |
Cpz |
carboxypeptidase Z |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CPZ mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:80,402,946...80,426,203
Ensembl chr14:80,403,001...80,426,245
|
|
G |
Crh |
corticotropin releasing hormone |
increases expression |
ISO |
Pioglitazone results in increased expression of CRH mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CRHR2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:85,286,371...85,329,374
Ensembl chr 4:85,286,372...85,329,362
|
|
G |
Crispld1 |
cysteine-rich secretory protein LCCL domain containing 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CRISPLD1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:663,750...711,033
Ensembl chr 5:670,754...711,033
|
|
G |
Crp |
C-reactive protein |
affects expression decreases expression |
EXP ISO |
pioglitazone affects the expression of CRP protein Pioglitazone results in decreased expression of CRP protein |
CTD |
PMID:28705172 PMID:28744220 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CRYAB mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CRYAB mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545
|
|
G |
Crym |
crystallin, mu |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CRYM mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:189,944,895...189,960,069
Ensembl chr 1:189,944,895...189,960,073
|
|
G |
Csn1s1 |
casein alpha s1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CSN1S1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:21,993,450...22,009,308
Ensembl chr14:21,993,427...22,009,308
|
|
G |
Csrp3 |
cysteine and glycine rich protein 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CSRP3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:104,147,205...104,166,389
Ensembl chr 1:104,147,206...104,166,367
|
|
G |
Ctla4 |
cytotoxic T-lymphocyte-associated protein 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CTLA4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:67,699,397...67,706,068
Ensembl chr 9:67,699,379...67,706,065
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CTNNB1 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases response to substance multiple interactions |
ISO |
pioglitazone results in decreased susceptibility to CXCL12 protein [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CXCL12 mRNA pioglitazone inhibits the reaction [CXCL12 protein affects the localization of ICAM3 protein] |
CTD |
PMID:18158351 PMID:27935865 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CXCL2 mRNA; [pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA |
CTD |
PMID:27935865 PMID:28263783 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of CXCL3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in increased expression of CXCL5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:18,860,201...18,920,839
Ensembl chr14:18,860,264...18,862,407
|
|
G |
Cxcr3 |
C-X-C motif chemokine receptor 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CXCR3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:71,614,346...71,616,997
Ensembl chr X:71,614,346...71,616,997
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of CXCR4 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression affects activity |
ISO |
pioglitazone results in decreased expression of CYBA mRNA pioglitazone affects the activity of CYBA protein |
CTD |
PMID:11172467 PMID:21962020 |
|
NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions decreases expression decreases activity |
ISO |
pioglitazone inhibits the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in increased activity of CYP17A1 protein]; pioglitazone inhibits the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in increased expression of CYP17A1 mRNA] pioglitazone results in decreased expression of CYP17A1 mRNA pioglitazone results in decreased activity of CYP17A1 protein |
CTD |
PMID:15072549 PMID:17138841 |
|
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression |
EXP ISO |
pioglitazone results in increased expression of CYP2B1 mRNA Pioglitazone results in increased expression of CYP2B10 mRNA |
CTD |
PMID:16597547 PMID:28541575 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
pioglitazone results in increased expression of CYP2B6 protein |
CTD |
PMID:12642470 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
increases expression |
ISO |
Pioglitazone results in increased expression of CYP2C55 mRNA |
CTD |
PMID:28541575 |
|
NCBI chr 1:258,074,797...258,139,176
Ensembl chr 1:258,074,860...258,139,176
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
multiple interactions increases expression decreases activity affects metabolic processing |
ISO |
Gemfibrozil inhibits the reaction [CYP2C8 protein affects the metabolism of pioglitazone] Pioglitazone results in increased expression of CYP2C8 mRNA pioglitazone results in decreased activity of CYP2C8 protein |
CTD |
PMID:12642470 PMID:15900286 PMID:31233785 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp2g1 |
cytochrome P450, family 2, subfamily g, polypeptide 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CYP2G1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:83,626,639...83,638,154
Ensembl chr 1:83,626,639...83,637,780
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [Endotoxins results in decreased expression of CYP3A2 protein] |
CTD |
PMID:15364003 |
|
NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression |
EXP |
Pioglitazone results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:16597547 |
|
NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases expression multiple interactions affects metabolic processing decreases activity |
ISO |
Pioglitazone results in increased expression of CYP3A4 mRNA; Pioglitazone results in increased expression of CYP3A4 protein [Pioglitazone results in increased expression of CYP3A4 protein] which results in decreased abundance of Ethinyl Estradiol; [Pioglitazone results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; Pioglitazone results in increased expression of and results in increased activity of CYP3A4 protein CYP3A4 protein affects the metabolism of Pioglitazone Pioglitazone results in decreased activity of CYP3A4 protein |
CTD |
PMID:12642470 PMID:15860655 PMID:15900286 PMID:16837568 PMID:22524704 PMID:31233785 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases expression |
ISO |
pioglitazone promotes the reaction [U 0126 results in increased expression of CYP7A1 mRNA]; U 0126 promotes the reaction [pioglitazone results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:22593575 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Dcaf12l1 |
DDB1 and CUL4 associated factor 12-like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DCAF12L1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:131,340,045...131,344,038
Ensembl chr X:131,340,045...131,343,853
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DDAH1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:251,634,368...251,766,009
Ensembl chr 2:251,634,431...251,766,014
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
multiple interactions increases expression |
ISO |
[Metformin co-treated with Pioglitazone] results in increased expression of DDIT4 mRNA Pioglitazone results in increased expression of DDIT4 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
multiple interactions increases expression |
ISO |
[Metformin co-treated with Pioglitazone] results in increased expression of DDIT4L mRNA Pioglitazone results in increased expression of DDIT4L mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 2:242,882,219...242,885,088
Ensembl chr 2:242,882,306...242,885,131
|
|
G |
Depp1 |
DEPP1, autophagy regulator |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DEPP1 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DEPP1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 4:148,780,330...148,784,566
Ensembl chr 4:148,782,479...148,784,562
|
|
G |
Deptor |
DEP domain containing MTOR-interacting protein |
multiple interactions |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of DEPTOR mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 7:94,795,161...95,000,750
Ensembl chr 7:94,795,214...94,995,809
|
|
G |
Derl3 |
derlin 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DERL3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:13,692,102...13,707,645
Ensembl chr20:13,704,314...13,706,205
|
|
G |
Des |
desmin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DES mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:82,556,574...82,564,288
Ensembl chr 9:82,556,573...82,564,294
|
|
G |
Deup1 |
deuterosome assembly protein 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DEUP1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:14,094,742...14,157,232
Ensembl chr 8:14,094,732...14,157,141
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
increases expression |
ISO |
pioglitazone results in increased expression of DGAT1 mRNA |
CTD |
PMID:20723549 |
|
NCBI chr 7:117,566,363...117,576,735
Ensembl chr 7:117,566,368...117,576,737
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
increases expression |
ISO |
pioglitazone results in increased expression of DGAT2 mRNA |
CTD |
PMID:20723549 |
|
NCBI chr 1:164,113,459...164,143,818
Ensembl chr 1:164,113,459...164,143,818
|
|
G |
Dhrs7c |
dehydrogenase/reductase 7C |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DHRS7C mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:54,352,270...54,370,653
Ensembl chr10:54,352,270...54,370,653
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
increases activity increases expression multiple interactions |
ISO |
pioglitazone results in increased activity of DIO2 protein pioglitazone results in increased expression of DIO2 mRNA PPARG protein promotes the reaction [pioglitazone results in increased activity of DIO2 protein] |
CTD |
PMID:19036883 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases activity |
ISO |
pioglitazone results in decreased activity of DIO3 protein |
CTD |
PMID:19036883 |
|
NCBI chr 6:134,627,278...134,629,139
Ensembl chr 6:134,627,278...134,629,138
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of DLG1 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr11:72,164,566...72,378,895
Ensembl chr11:72,163,749...72,378,895
|
|
G |
Dmbt1 |
deleted in malignant brain tumors 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DMBT1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:201,620,642...201,689,905 NCBI chr 1:203,149,414...203,228,705
|
|
G |
Dnaaf2 |
dynein, axonemal, assembly factor 2 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of DNAAF2 mRNA; pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of DNAAF2 mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 6:91,481,439...91,490,189
Ensembl chr 6:91,481,954...91,490,366
|
|
G |
Dnah8 |
dynein, axonemal, heavy chain 8 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DNAH8 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr20:9,301,317...9,560,805
Ensembl chr20:9,313,271...9,560,682
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DNER mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 9:91,965,866...92,291,172
Ensembl chr 9:91,965,866...92,291,220
|
|
G |
Dpt |
dermatopontin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DPT mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:83,073,307...83,102,404
Ensembl chr13:83,073,544...83,102,401
|
|
G |
Dpy19l2 |
dpy-19 like 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DPY19L2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:25,710,492...25,829,589
Ensembl chr 8:25,710,472...25,829,569
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DRD1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of DUSP10 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455
|
|
G |
Dusp26 |
dual specificity phosphatase 26 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of DUSP26 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:64,798,782...64,806,459
Ensembl chr16:64,798,778...64,806,050
|
|
G |
Dusp27 |
dual specificity phosphatase 27, atypical |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of DUSP27 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr13:84,302,824...84,332,899
Ensembl chr13:84,302,830...84,331,905
|
|
G |
Eddm3b |
epididymal protein 3B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of EDDM3B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr15:28,090,836...28,094,548
Ensembl chr15:28,090,836...28,092,023
|
|
G |
Eef1a2 |
eukaryotic translation elongation factor 1 alpha 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of EEF1A2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:176,657,104...176,666,282
Ensembl chr 3:176,657,107...176,666,282
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of EGF mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egflam |
EGF-like, fibronectin type III and laminin G domains |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of EGFLAM mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:56,503,002...56,681,334
Ensembl chr 2:56,502,807...56,679,955
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
[Metformin co-treated with Pioglitazone] results in decreased expression of EIF4E mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 2:243,819,616...243,853,987
Ensembl chr 2:243,820,661...243,852,631
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions increases expression decreases phosphorylation |
ISO |
pioglitazone inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased expression of EIF4EBP1 protein] Pioglitazone results in increased expression of EIF4EBP1 mRNA pioglitazone results in decreased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:26643070 PMID:32589349 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Eif4ebp2 |
eukaryotic translation initiation factor 4E binding protein 2 |
increases expression |
ISO |
Pioglitazone results in increased expression of EIF4EBP2 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr20:31,055,292...31,072,469
Ensembl chr20:31,055,789...31,072,469
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
increases expression |
ISO |
pioglitazone results in increased expression of EIF5A mRNA |
CTD |
PMID:21347706 |
|
NCBI chr10:56,527,075...56,531,615
Ensembl chr10:56,527,085...56,531,483
|
|
G |
Elovl4 |
ELOVL fatty acid elongase 4 |
increases expression |
ISO |
Pioglitazone results in increased expression of ELOVL4 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 8:91,310,690...91,338,625
Ensembl chr 8:91,310,630...91,338,843
|
|
G |
Eno3 |
enolase 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ENO3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:57,278,271...57,283,661
Ensembl chr10:57,278,307...57,283,653
|
|
G |
Epgn |
epithelial mitogen |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of EPGN mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:18,627,103...18,635,135
Ensembl chr14:18,626,644...18,634,309
|
|
G |
Epha3 |
Eph receptor A3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of EPHA3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:421,253...783,037
Ensembl chr11:421,135...782,954
|
|
G |
Epha5 |
EPH receptor A5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of EPHA5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:25,589,312...25,958,258
Ensembl chr14:25,589,762...25,958,227
|
|
G |
Epyc |
epiphycan |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of EPYC mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:38,897,278...38,934,989
Ensembl chr 7:38,897,278...38,934,985
|
|
G |
Erbin |
erbb2 interacting protein |
multiple interactions |
ISO |
pioglitazone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ERBIN mRNA] |
CTD |
PMID:20847119 |
|
NCBI chr 2:33,880,860...33,952,806
Ensembl chr 2:33,881,024...33,920,837
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Pioglitazone results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
|
|
G |
F10 |
coagulation factor X |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of F10 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:81,803,169...81,822,476
Ensembl chr16:81,803,110...81,822,716
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FABP3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:148,528,854...148,535,597
Ensembl chr 5:148,528,725...148,535,565
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO |
[pioglitazone co-treated with Tretinoin] results in increased expression of FABP4 mRNA Pioglitazone results in increased expression of FABP4 mRNA pioglitazone results in increased expression of FABP4 mRNA Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone promotes the reaction [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA] |
CTD |
PMID:9543393 PMID:12927809 PMID:15273253 PMID:16573735 PMID:17290005 PMID:19048458 PMID:30031879 PMID:32473317 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Fam13a |
family with sequence similarity 13, member A |
increases expression |
ISO |
Pioglitazone results in increased expression of FAM13A mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 4:89,183,180...89,281,282
Ensembl chr 4:89,183,768...89,281,222
|
|
G |
Fam171b |
family with sequence similarity 171, member B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FAM171B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:71,210,048...71,265,419
Ensembl chr 3:71,210,301...71,262,615
|
|
G |
Fam184b |
family with sequence similarity 184, member B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FAM184B mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:69,970,034...70,086,018
Ensembl chr14:70,015,754...70,086,143
|
|
G |
Fam210a |
family with sequence similarity 210, member A |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of FAM210A mRNA |
CTD |
PMID:20847119 |
|
NCBI chr18:64,045,023...64,084,594
Ensembl chr18:64,045,432...64,084,556
|
|
G |
Fam240b |
family with sequence similarity 240 member B |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of FAM240B mRNA |
CTD |
PMID:27935865 |
|
Ensembl chr17:1,994,172...1,999,596
|
|
G |
Fam47e |
family with sequence similarity 47, member E |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FAM47E mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:16,991,496...17,027,563
|
|
G |
Fat4 |
FAT atypical cadherin 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FAT4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 2:125,751,818...125,879,398
Ensembl chr 2:125,752,130...125,879,387 Ensembl chr 2:125,752,130...125,879,387
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
ISO |
Pioglitazone results in increased expression of FBLN1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 7:126,096,793...126,176,468
Ensembl chr 7:126,096,793...126,176,468
|
|
G |
Fbln7 |
fibulin 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FBLN7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:121,407,981...121,441,660
Ensembl chr 3:121,408,146...121,440,787
|
|
G |
Fbxl16 |
F-box and leucine-rich repeat protein 16 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FBXL16 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr10:15,176,489...15,188,729
Ensembl chr10:15,183,803...15,186,978
|
|
G |
Fbxo40 |
F-box protein 40 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FBXO40 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:66,713,913...66,731,195
Ensembl chr11:66,713,888...66,731,198
|
|
G |
Fbxo43 |
F-box protein 43 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FBXO43 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:74,925,091...74,938,796
Ensembl chr 7:74,925,092...74,938,663
|
|
G |
Fcmr |
Fc fragment of IgM receptor |
increases expression |
ISO |
Pioglitazone results in increased expression of FCMR mRNA |
CTD |
PMID:30031879 |
|
NCBI chr13:47,602,701...47,617,065
Ensembl chr13:47,602,692...47,617,064
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
increases expression |
ISO |
pioglitazone results in increased expression of FGF21 mRNA |
CTD |
PMID:21720023 |
|
NCBI chr 1:101,595,579...101,596,822
Ensembl chr 1:101,595,579...101,596,822
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FGF7 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
|
|
G |
Fgl1 |
fibrinogen-like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FGL1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:54,153,086...54,188,120
Ensembl chr16:54,153,054...54,188,181
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
increases expression |
ISO |
Pioglitazone results in increased expression of FHL1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr X:159,112,516...159,172,528
Ensembl chr X:159,112,880...159,172,524
|
|
G |
Filip1 |
filamin A interacting protein 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FILIP1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:87,257,312...87,453,432
Ensembl chr 8:87,256,264...87,419,564
|
|
G |
Fjx1 |
four-jointed box kinase 1 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of FJX1 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 3:92,288,818...92,290,919
Ensembl chr 3:92,288,818...92,290,919
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
increases expression |
ISO |
Pioglitazone results in increased expression of FKBP1A mRNA |
CTD |
PMID:32589349 |
|
NCBI chr 3:147,042,944...147,062,725
Ensembl chr 3:147,042,944...147,062,724
|
|
G |
Fkbp8 |
FKBP prolyl isomerase 8 |
increases expression |
ISO |
Pioglitazone results in increased expression of FKBP8 mRNA |
CTD |
PMID:32589349 |
|
NCBI chr16:20,645,956...20,652,890
Ensembl chr16:20,645,957...20,652,889
|
|
G |
Flnc |
filamin C |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FLNC mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:56,710,934...56,738,779
Ensembl chr 4:56,711,049...56,738,791
|
|
G |
Fndc5 |
fibronectin type III domain containing 5 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FNDC5 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 5:147,323,240...147,330,266
Ensembl chr 5:147,323,240...147,330,266
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
pioglitazone results in increased expression of FOS mRNA |
CTD |
PMID:11687581 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of FOSB mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:80,214,691...80,221,417
Ensembl chr 1:80,214,494...80,221,710
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of FOSL1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Foxn4 |
forkhead box N4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FOXN4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr12:48,101,012...48,121,281
Ensembl chr12:48,101,673...48,121,270
|
|
G |
Fpr1 |
formyl peptide receptor 1 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of FPR1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 1:59,759,025...59,767,258
Ensembl chr 1:59,765,835...59,767,042
|
|
G |
Frzb |
frizzled-related protein |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FRZB mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 3:67,635,604...67,668,772
Ensembl chr 3:67,635,607...67,668,772
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of FSCN1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr12:13,655,459...13,668,595
Ensembl chr12:13,656,554...13,668,515
|
|
G |
Fsd2 |
fibronectin type III and SPRY domain containing 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FSD2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:143,364,867...143,398,123
Ensembl chr 1:143,364,867...143,398,093
|
|
G |
Fxyd1 |
FXYD domain-containing ion transport regulator 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of FXYD1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:89,484,197...89,488,279
Ensembl chr 1:89,484,199...89,488,223
|
|
G |
Gabra3 |
gamma-aminobutyric acid type A receptor subunit alpha 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GABRA3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr X:152,414,332...152,642,607
Ensembl chr X:152,414,615...152,642,531
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GABRA4 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr14:39,154,072...39,230,994
Ensembl chr14:39,154,529...39,231,695
|
|
G |
Galnt16 |
polypeptide N-acetylgalactosaminyltransferase 16 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GALNT16 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 6:104,069,853...104,250,177
Ensembl chr 6:104,068,547...104,250,174
|
|
G |
Galnt17 |
polypeptide N-acetylgalactosaminyltransferase 17 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with Pioglitazone] results in decreased expression of GALNT17 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr12:28,381,879...29,268,457
Ensembl chr12:28,381,982...29,268,073
|
|
G |
Galnt9 |
polypeptide N-acetylgalactosaminyltransferase 9 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of GALNT9 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr12:52,106,506...52,187,205
Ensembl chr12:52,106,506...52,187,164
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in increased expression of GDF15 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Gem |
GTP binding protein overexpressed in skeletal muscle |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in increased expression of GEM mRNA |
CTD |
PMID:20847119 |
|
NCBI chr 5:25,339,479...25,353,661
Ensembl chr 5:25,349,928...25,353,661
|
|
G |
Gemin4 |
gem (nuclear organelle) associated protein 4 |
multiple interactions |
ISO |
[pioglitazone co-treated with tert-Butylhydroperoxide] results in decreased expression of GEMIN4 mRNA |
CTD |
PMID:20847119 |
|
NCBI chr10:64,364,808...64,375,885
Ensembl chr10:64,368,809...64,375,816
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GFRA1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:279,203,046...279,572,789
|
|
G |
Gh1 |
growth hormone 1 |
increases expression |
ISO |
Pioglitazone results in increased expression of GH1 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr10:94,486,204...94,488,181
Ensembl chr10:94,486,205...94,488,180
|
|
G |
Gimap4 |
GTPase, IMAP family member 4 |
decreases expression |
ISO |
Pioglitazone results in decreased expression of GIMAP4 mRNA |
CTD |
PMID:30031879 |
|
NCBI chr 4:78,320,230...78,327,144
Ensembl chr 4:78,320,190...78,327,144
|
|
G |
Gldn |
gliomedin |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GLDN mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 8:58,870,516...58,914,605
Ensembl chr 8:58,870,516...58,914,603
|
|
G |
Gmnc |
geminin coiled-coil domain containing |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GMNC mRNA |
CTD |
PMID:27935865 |
|
NCBI chr11:77,237,033...77,247,723
Ensembl chr11:77,239,098...77,246,315
|
|
G |
Gnat3 |
G protein subunit alpha transducin 3 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GNAT3 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 4:13,827,764...13,878,126
Ensembl chr 4:13,827,756...13,878,126
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
pioglitazone inhibits the reaction [[Ethanol co-treated with Lipopolysaccharides] results in increased expression of GOT1 protein] |
CTD |
PMID:15318101 |
|
NCBI chr 1:263,246,248...263,269,762
Ensembl chr 1:263,246,248...263,269,762
|
|
G |
Got1l1 |
glutamic-oxaloacetic transaminase 1-like 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GOT1L1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:69,022,756...69,035,507
Ensembl chr16:69,022,784...69,028,179
|
|
G |
Gp2 |
glycoprotein 2 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GP2 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 1:189,166,735...189,182,306
Ensembl chr 1:189,166,399...189,182,306
|
|
G |
Gpihbp1 |
glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GPIHBP1 mRNA |
CTD |
PMID:27935865 |
|
NCBI chr 7:116,632,496...116,635,543
Ensembl chr 7:116,632,506...116,634,293
|
|
G |
Gpm6a |
glycoprotein m6a |
multiple interactions |
ISO |
[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of GPM6A mRNA |
CTD |
PMID:27935865 |
|
NCBI chr16:39,367,697...39,719,292
Ensembl chr16:39,367,692...39,719,187
|
|
G |
Gpr183 |
G protein-coupled receptor 183 |
|